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ABSTRACT
The main objectives of this dissertation were to provide a complete depiction of
the prevalence of HIV across the United States and to assess HIV testing trends among
various subpopulations. Additionally, we focused on measuring spatial access to HIVtesting resources across the U.S. South, where HIV is rapidly becoming more
burdensome and resources have historically been allocated disproportionately. We sought
to identify disparate populations and locations that require further focus moving forward
to stem the HIV epidemic.
We utilized a variety of data sources such as the Behavioral Risk Factor
Surveillance System (BRFSS) which was used to assess national temporal trends of
reported HIV testing among different subpopulations. We used geocoded HIV facility
locations, obtained from the Centers for Disease Control and Prevention (CDC), to
examine spatial accessibility to HIV testing facilities with a focus on rurality, across the
U.S. south. We applied small area estimation (SAE) techniques to model HIV prevalence
at the county-level, using auxiliary covariate data and HIV data released by the CDC, to
assess the burden of HIV at the local level.
Our study found that as rurality increased, as did suboptimal access to HIV testing
facilities across the U.S. south, particularly in more socioeconomically deprived areas.
Populations farther than 30 minutes from a testing facility, had lower average median
household incomes, higher poverty rates and higher rates of being uninsured. We also
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found nationwide that females, individuals with health insurance, those who identify as
lesbian/gay and partake in high risk behaviors were more likely to report being tested for
HIV compared to males, individuals without insurance, those who identify as straight and
those who do not partake in high risk behaviors. Our findings also confirmed previous
research showing the highest prevalence of HIV along the coastlines and consistently
across the U.S. south.
Overall, the work from this dissertation indicates the continued need for targeted
interventions, outreach efforts and policies to address disparities regarding the utilization
of HIV testing across the country, particularly along the coasts and in the rural south
where there is a disproportionate level of access to HIV testing services.

Keywords: HIV, HIV testing, HIV prevalence, small area estimation, geographic
information systems, spatial analysis, health disparities
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CHAPTER 1

INTRODUCTION

Human immunodeficiency virus (HIV) has been in the global spotlight for the
better part of the past three decades with the first cases being diagnosed in the early
1980s to an estimated 36.7 million people living with HIV worldwide as of 2015
(“Global AIDS Update” 1). HIV rates have steadily declined in the U.S. over the past
decade, with new HIV diagnoses dropping by almost 20% from 2005 to 2014 (“Global
AIDS Update”). While a concerted effort to lower the rate of HIV burden in urban areas
has resulted in an 18% decline in new HIV infections as per the CDC, HIV incidence and
prevalence rates have increased in rural areas over the past two decades (Pellowski et al.).
Still over 90% of HIV cases in the U.S. occur in major urban areas but due to the sparsity
of people in many rural areas, the proportion of the population affected by HIV can be as
high if not higher in rural areas compared to their urban counterparts (“HIV/AIDS in
Rural America” 1).
In 2008, the Centers for Disease Control and Prevention (“HIV in the United
States”) estimated that 49,645 adults and adolescents were living with HIV in rural areas
of the U.S. (“HIV in the United States”) and that HIV is having an increasing impact on
these communities. As recently as 2015, Indiana experienced the largest outbreak of HIV
in its state history and a small, rural community was the epicenter (Ungar).
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Indiana is an alarming example of a rural community that was primed for an HIV
epidemic given its HIV risk indicators- high prescription painkiller and injection drug
use, high unemployment rates, high poverty rates, low levels of education, poor access to
healthcare and the low rates of life expectancy in the state (Vyavaharkar).
The uptick in HIV rates coupled with other poor health indicators in rural areas
particularly in the south (e.g. high rates of death, diabetes and heart disease) (Reif) did
not however lead to an increased focus of research or community outreach in those areas
until recently. Rather, the focus on HIV has been missing from many rural communities
and has led to the current state of rural health. Furthermore, studies done examining
spatial accessibility to HIV related services are either out of date or too small in scope
(Dasgupta) to be of much use nationally. There are major concerns regarding incomplete
information available on HIV prevalence, access and utilization of HIV resources across
the country. Partial data on HIV prevalence rates at the county level up to 2014 is
publicly available although rates for large segments of the Midwest and fragments across
the rest of the country are missing due to small HIV counts (< 5) in those sparsely
populated areas or due to agreements with the state health department to not release such
information (such as in South Dakota).

1.1 Statement of the Problem
There is a major gap in the literature examining spatial accessibility and proximity
to HIV testing. Current research on the subject is either urban setting specific (Dasgupta;
Ganapati) or done outside of the United States (Fulcher). We planned to utilize and
expand upon the measures and research done by previous studies but on a nationally
representative scale. In addition, there is a lack of publicly available data when it comes
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to HIV prevalence across the country. Federal agencies like the CDC have released
incomplete surveillance reports, suppressing data on HIV prevalence at the county level
in various parts of the nation particularly in the Midwest. This is due to one or a
combination of the following factors: low HIV count in a small population,
missing/unreported data or per the request of the state. Regardless of the rationale,
incomplete publicly available data is a problem as it can mask areas with potential HIV
problems that can then spread to other communities. There is also very little research on
HIV testing rates across areas or population subgroups using data from population-based
health surveys such as the Behavioral Risk Factor Surveillance System (BRFSS). There
have been studies done using BRFSS data within the past five years, but most have only
focused on specific geographic regions or specific subpopulations (Ansa and Ford) but
have not utilized the most current data available on a larger scale.
While it is true that nearly half of all people living with acquired
immunodeficiency syndrome (AIDS) reside in ten metropolitan areas across the country
(Pellowski et al. 3) there are increasingly substantial pockets of HIV occurring in rural
America, especially in the south, where there is a lack of focus on HIV surveillance and
interventions. The spread of HIV is based on local prevalence, individual behaviors,
biological factors and social conditions (Pellowski et al. 2). There have been
interventions and policies targeting these factors to some extent since HIV came into the
public light (Donley). However, interventions and policies are normally directed at areas
where an issue has been assessed, researched and needs correction. However, rural areas
can be easily overlooked due to funding restrictions, lack of planning and surveillance
activities, and misconceptions about population risk factors. Incomplete, missing, or old
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data in rural areas hamper efforts to combat rising HIV transmission and can lead to
dangerous mismanagement or misidentification of potential HIV hot spots in the future.
1.2 Aims and Hypotheses
The goal of this project is to provide valuable and updated information on
different aspects of HIV surveillance in the U.S. This dissertation covered a spectrum of
topics ranging from examining spatial accessibility to HIV-testing related resources in the
U.S. South (Paper 1), providing more complete and updated estimates of HIV prevalence
across all U.S. counties (Paper 2), and assessing HIV testing trends to identify
subpopulations in need of support (Paper 3). The specific aims are as follows:
Aim 1: To examine spatial accessibility to HIV testing facilities across the U.S. South,
along with measures of area socioeconomic deprivation and other HIV risk indicators
which can increase the probability of an HIV epidemic.
Hypothesis 1: As rurality increases, we hypothesized that residents will experience
suboptimal access to HIV testing-related resources, particularly in more socioeconomic
deprived areas. We also hypothesized that areas with higher proportions of minorities,
regardless of the level of rurality of the area, will exhibit lower levels of spatial
accessibility to HIV testing facilities.
Rationale: Research shows that factors such as lack of qualified providers with HIV
expertise, transportation issues, and stigma can lead to social isolation and play a role in
the transmission of HIV (Pellowski 6). These issues are particularly relevant in rural
areas where there are fewer options for public transportation and medical providers. In
addition, a more tight-knit community leads to a higher likelihood of people finding out if
someone has HIV (“HIV/AIDS in Rural America”). Late diagnosis and linkage to HIV
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care of HIV was also found to be associated with rurality in previous studies (Trepka;
Holtgrave). Hence the focus of this aim was to identify if and where there was a disparity
of access to HIV testing across the U.S. South. As well as to determine disparities
coupled with other HIV risk factors (e.g., insurance coverage, employment status,
education status) which can be used to identify potential HIV hotspots/outbreaks.

Aim 2: To estimate HIV prevalence at the county level and to compare prevalence across
the country to identify areas with high HIV burden.
Hypothesis 2: We hypothesized that the HIV prevalent case counts predicted by our SAE
model will be considered valid and reliable after statistical validation techniques.
Rationale: There are many counties across the United States without publicly available
data on HIV prevalence due to being either missing or suppressed. These areas are
majority located in rural areas where while the population sizes may be small and spread
out, the proportional burden of HIV may be just as great as in more populated areas
(“HIV/AIDS in Rural America” 1). Hence the need to estimate rates in those missing
areas to better understand the epidemic and find potential hot-spots based on HIV-risk
indictors. Risk indicators like high rates of poverty, unemployment and poor education
levels, all of which disproportionately plague minority groups. In turn, minority groups
are disproportionality burdened with HIV such as African Americans who made up 44%
of all new HIV diagnoses in 2009 but only make up 14% of the general population (“HIV
in the United States). Areas with high levels of economic deprivation also have the
lowest levels of social capital, or the value of one’s social network, which has been
documented to be associated with higher rates of HIV infection (Cao). We believe that
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the inclusion of all of these factors into our model will provide strength for our model to
accurately predict the prevalence of HIV across the country.
Aim 3: To explore HIV testing rates and individual-level determinants among different
population subgroups over time using BRFSS data from 2011-2017.
Hypothesis 3: We hypothesized that utilization of HIV testing will be lower among
minority groups, individuals without access to insurance and among males in general.
Rationale: Being tested for HIV is important in stemming the spread of HIV however as
mentioned, HIV affects minorities disproportionately (Pellowski et al.). While there have
been major strides made in increasing access to HIV testing to stem transmission, through
interventions and advancement in technology (“HIV Surveillance Report”), the progress
is not equal across all segments of the U.S. population. Even among minority groups, the
greatest burden of disease generally follows socioeconomic lines, with the greatest
burden observed among the poorest (Pellowski et al. 3).
The overall focus of these aims was to provide a clearer picture of the spatial
access to HIV-testing related resources across the U.S. South, utilization of testing
resources and assessing the progress made. We also provided insight into HIV prevalence
in areas where there was no public data previously available, across the nation to identify
disparate populations and locations that require further focus moving forward.
1.3 Importance of Research
This dissertation updated and filled in gaps in the literature regarding the current
state of access to HIV-related resources to all regions and population subgroups in the
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south where HIV is a growing problem. It used the largest publicly available national
health-related survey (e.g., BRFSS) to assess trends in HIV testing over time and identify
subpopulations that have particularly low (or declining) rates of HIV testing. We also
provided a clearer picture of HIV prevalence across the U.S. by estimating prevalence
rates for areas that have no publicly available data to identify hot spots. This work is
significant in providing much needed attention to HIV in underserved and
disenfranchised communities nationwide, both in terms of access to HIV related
resources and epidemiologic measures (i.e. prevalence rates). With the shifting
demographics of the disease in recent years (P.B. Williams) as well as parallel trends in
drug abuse, poverty and healthcare facility closures in rural America (Helseth), a renewed
focus on the entire country, especially rural areas, was warranted.
It has been assumed for many years that HIV is solely an urban, big city problem,
including people in rural areas who believe it can never happen in their close-knit
integrated communities (“Pellowksi”). While new AIDS diagnoses have been declining
in urban settings over the past 30 years, they have slowly been increasing in rural settings
particularly in the south where 8.6% of new AIDS diagnoses in 2011 were from
nonmetropolitan areas (“HIV Surveillance Report”).
A major obstacle in determining the burden of HIV in rural settings is the small
population sizes which as mentioned leads to a tight-knit community where keeping a
diagnosis private can be problematic and hence people are less likely to volunteer to be
tested and hence underreported rates (Oppong). This dissertation was innovative in how
it tackled the issue of inexact reporting in rural settings through area-level small area
estimation modeling technique which will borrow strength from available HIV rates in
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neighboring counties and utilize data on HIV risk factors in the community to
approximate the HIV burden in the area. The results from this dissertation will help
identify disenfranchised groups and weaknesses across the country where HIV-related
disparities are present and need to be addressed.
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CHAPTER 2

BRIEF LITERATURE REVIEW OF THE HIV EPIDEMIC SINCE THE
1980s

2.1 History and Risk Factors
To better understand a disease and how to combat its spread, it is important to
understand the history and timeline of important events and policies that have led to the
current disease landscape. There have been major historical changes since HIV was first
thrust into the public spotlight in 1981; these changes have helped contain the spread of
HIV in many but not settings.
The Human Immunodeficiency Virus is thought to have originated back in the
1920s when the Simian immunodeficiency virus (SIV) that infected chimpanzees crossed
over to infect humans in the Democratic Republic of the Congo (DRC). Scientists believe
the earliest case positively identified as Acquired Immunodeficiency Syndrome (AIDS)
was a man in the DRC in 1959 although it has been disputed by some researchers as truly
being AIDS as defined later (Worobey). While HIV was not publicly introduced to the
American public until the early 1980s, Scientists believe the “patient zero” (“A Timeline
of HIV and AIDS”) for HIV in the U.S., traveled to New York from Haiti, a full decade
earlier and the disease had been misclassified for years.
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The first public introduction to what would later be deemed as AIDS came in
1981 when five young gay men in the Los Angeles Area were diagnosed with a rare form
of pneumonia. Along with the pneumonia, the men had other infections resulting from
weakened immune systems. These were the first of many reported cases of the rare form
of pneumonia among gay men as well as Kaposi’s Sarcoma (KS) - a rare form of cancer,
reported among a group of gay men in New York and California. Early in the HIV/AIDS
epidemic, the disease was coined a “gay cancer” and many in the public as well as some
in the medical community shared the sentiment that this was an exclusively homosexual
disease. Some in the medical community termed the disease “Gay-Related Immune
Deficiency or “GRID” (“A Cluster of Kaposi’s Sarcoma”). At this point the case total
had risen to over 250 with a fatality rate nearing 50% among immunocompromised gay
men (“A Timeline of HIV and AIDS”). The CDC in 1982 coined the term “Acquired
Immune Deficiency Syndrome” or ‘AIDS” and an official case-definition for the disease
(“A Timeline of HIV and AIDS”). It was soon after this in 1983 that AIDS cases were
found among female partners of men with AIDS (“Epidemiological Notes”) as well as
children who had received blood transfusions from a male later to have been diagnosed
with AIDS (“A Timeline of HIV and AIDS”).
In 1983, the CDC published the first recommended precautions for healthcare
workers and allied health professionals to prevent "AIDS transmission” and Congress
passed its first bill funding AIDS research and treatment- allocating approximately $12
million for such efforts (“Current Trends Update”). The CDC would provide further
clarification on AIDS transmission, notably dismissing the thought of AIDS being
transmitted through “food, water, air, or environmental surfaces” (“A Timeline of HIV

10

and AIDS”). Later that year, two laboratories- one led by Dr. Luc Montagnier of the
Pasteur Institute in France and another led by Dr. Robert Gallo of the National Cancer
Institute, separately isolated strains that they each believe are related to AIDS, labeled the
lymphadenopathy-associated virus (LAV) by Montagnier, and HTLV-III by Gallo (“A

Timeline of HIV and AIDS”). They would hold a joint press conference classifying their
discoveries as a retrovirus claimed to be the cause of AIDS. In 1986, these viruses, after
being deemed the same, would be given the official name of the Human
Immunodeficiency Virus (HIV) by the International Committee on the Taxonomy of
Viruses (“A Timeline of HIV and AIDS”).
In 1985 Ryan White, a teenager from Indiana, who had acquired AIDS through
contaminated blood products to treat his hemophilia, was barred from his school due to
his condition. This led to national media attention after the White family procured legal
services to battle for Ryan’s rights (“Who is Ryan White?”). Ryan White would live for
another 5 years before his death in 1990, several months before the passing of the Ryan
White CARE Act 27-which helped to establish a comprehensive system of care that
includes primary medical care and essential support services for PLWHV who are
uninsured or underinsured. It was soon after this initial media attention that AIDS was
officially mentioned for the first time on a public scale by President Ronald Regan. That
same year, the National AIDS Network (NAN) was founded as was American
Foundation for AIDS Research (amfAR).
Replicating efforts initiated in Europe, the first needle exchange program (NEP)
started in Connecticut to stem transmission of HIV in 1986. Now there are over 200
NEPs across 36 states as per CDC (“Needle Exchange”). There was an added focus on
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needle exchanges in general after the CDC added intravenous drug use (IDU) to the
growing list of risk factors for AIDS (i.e., men who have sex with men, Haitian origin,
hemophilia A, female sexual partners of men with AIDS). Reducing needle sharing and
IDU would help stem the transmission of HIV as the sharing of dirty needles is
considered a risk factor for HIV (“Needle Exchange”).
A breakthrough in HIV treatment occurred in 1987 with the FDA approval of the
first antiretroviral drug zidovudine (AZT), followed by the U.S. Congress backing of $30
million for production and distribution of AZT (“A Timeline of HIV and AIDS”). Later
that year, President Reagan would establish the Presidential Commission on HIV, also
known as the Watkins Commission, after his first public speech on AIDS. That same year
(1987), the U.S. government made two marquee policies regarding HIV/AIDS. The first
was a ban of all HIV-positive individuals from immigrating to the U.S. by adding HIV to
the “dangerous contagious disease” immigration exclusion list (“A Timeline of HIV and
AIDS”). The second was a congressional vote in favor of federally financing educational
material on AIDS to promote sexual abstinence and forbid the use of federal funds in the
production of any material promoting homosexuality and IDU use, officially termed the
“Helms Amendment” (“A Timeline of HIV and AIDS”).
As of 1989, the count of reported AIDS cases in the U.S. had grown to 100,000
amid growing interest and funding of HIV research. HRSA provided $20 million to
establish HIV care and treatment in the home and community at the state level across the
nation, many of which were receiving funding for HIV care for the first time. The Health
Resources and Services Administration (HRSA) and the CDC also partnered to provide
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funding for seven community health centers to provide HIV counseling and testing
(would later become a piece of the Ryan White CARE Act of 1990).
In 1990, the U.S. Congress added PLWH to the Americans with Disabilities Act
to prohibit discrimination against people with disabilities including HIV (“Global
HIV/AIDS Timeline”). This bill came one month prior to the Ryan White CARE Act
passage, providing over $220 million annually in federal funding for HIV care and
treatment at the community level. The end of 1990 brought about the enactment of the
AIDS Housing Opportunity Act, as well as the formation of the Latino Commission on
AIDS to identify the needs of the underserved Latino population regarding HIV
prevention and care (“A Timeline of HIV and AIDS”).
The rapid spread of HIV/AIDS would continue to take its toll on the country as it
was deemed in 1992 to be the number one cause of death among men, ages 25-44
(Stolberg). Later in the year, the FDA licensed a 10-minute testing kit which could be
used by healthcare professionals to detect HIV-1. At this point, federal funding for
HIV/AIDS research and care had reached $4.5 billion (more than double the amount
given just 3 years prior in 1989). The HIV Epidemiology Study (HERS) and the
Women’s Interagency HIV Study (WHIS) both started after congress enacted the
National Institutes of Health (NIH) revitalization act which mandated increased
involvement of women and minorities in all facets of research. On the other spectrum, the
8th annual International AIDS conference was moved from Boston to Amsterdam due to
the travel ban on HIV-positive individuals to the U.S.; a ban that the USA Congress
voted overwhelmingly to retain in 1993 and was included as part of the same NIH
revitalization act (2.5 million AIDS cases worldwide by this time).
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The spread of AIDS in the U.S. would grow to such an extent that from 19941995, it was deemed the number one cause of death among all Americans ages 25-44 (“A
Timeline of HIV and AIDS”). It would be later in 1994 that the U.S. Food and Drug
Administration (FDA) would approve use of an oral HIV test which was the first nonblood antibody test of its kind (“A Timeline of HIV and AIDS”). It was during this time
that the CDC would issue a report on the Syringe Exchange Programs (SEPs) deeming it
an effective HIV prevention strategy, a time that also saw the total cases of AIDS
diagnoses hit half a million in the U.S. (“A Timeline of HIV and AIDS”).
1996 was a turning point year in the fight against HIV/AIDS in that it was the first
year since the epidemic officially began, that saw a decline in the number of new AIDS
cases in the U.S. and HIV was no longer the leading cause of death among Americans
aged 25-44 in general; still the leading cause among African Americans that age
(“Update Mortality”). It was also the year the FDA made three major announcements
regarding HIV: 1) an HIV home testing and collection kit 2) a viral load test to measure
the amount of HIV in the blood and 3) the approval of nevirapine- a reverse transcriptase
inhibitor drug (“A Timeline of HIV and AIDS”). The following year saw the official shift
in standard treatment to highly active antiretroviral therapy (HAART) (“A Timeline of
HIV and AIDS”). A shift that saw the advent of Combivir, a 2 in 1 ART drug tablet made
that would cut down on the number of medication that patients would be required to take.
A final major development before the end of the 90s was the CDC expanding the
case definition of HIV for better surveillance and tracking of the epidemic (“A Timeline
of HIV and AIDS”). There was also a greater focus on the epidemic and its effect on the
Latino community through congressional hearings and attention from the U.S.
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Congressional Hispanic Caucus. At this point globally, HIV/AIDS had become the 4th
largest cause of death and was the leading cause of death in Africa. The World Health
Organization (WHO) noted that there were an estimated 33 million PLWH globally and
14 million had died from AIDS to that point.
While the U.S. had been concentrating on combating HIV/AIDS domestically, the
2000s saw a major shift internationally as the epidemic became more global. Major
political moves signifying this shift included the U.S. declaring HIV/AIDS a threat to
national security and the signing of an executive order providing assistance to developing
countries regarding the production and dissemination of HIV treatments. The U.S.
Congress enacted the Global AIDS and Tuberculosis Relief Act of 2000 to help in the
global fight against AIDS. Domestically, Congress reauthorized the Ryan White CARE
Act for the second time (“A Timeline of HIV and AIDS”).
In 2002, HIV would become the number one leading cause of death among ages
15-59 worldwide (“Global HIV/AIDS Timeline”), as the U.S. continued its support of
fighting the epidemic globally, particularly in developing countries. This focus in large
part was due to the alarming rates of HIV incidence in sub-Saharan Africa and the
inability of poor countries to develop the necessary pharmaceuticals for treatment. The
Global Fund to Fight AIDS, Tuberculosis and Malaria was created to combat the
epidemic by combining government and private efforts (“A Timeline of HIV and
AIDS”). The FDA also approved an innovative HIV test called the OraQuick Rapid HIV1 Antibody Test which rapidly tests for HIV with a finger prick and can be done in nonclinical settings (“A Timeline of HIV and AIDS”). This test would receive an update in
2004 with saliva added as a testing sample option.
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A couple of major biological discoveries occurred from 2005 to 2006. It was
discovered that approximately 1/10th of Europeans were immune to HIV due to genetic
adaptions during the plagues of the middle ages. Secondly, an HIV-like virus was found
in chimpanzees in south Cameroon, adding further evidence to the theory that HIV was
first contracted through human-chimpanzee contact. Researchers also found that male
circumcision was found to reduce the risk of female-to-male HIV transmission by up to
60% (“A Timeline of HIV and AIDS”).
In 2006, the CDC recommended a shift to the “opt-out” approach to HIV testing
for all adult and adolescent patients in health-care settings, including pregnant women
where HIV testing would be done unless the individual decides against it (“A Timeline of
HIV and AIDS”). Additional recommendations released by the CDC included yearly
testing for all individuals of age and the changing of HIV testing consent from separately
written to general medical care consent (“New Progress and Guidance”). Meanwhile the
WHO released its revised guidelines on HIV treatment, recommending that ART be
started for all patients with advanced clinical disease or a CD4 count of 200 cells/mm3 or
less (“WHO and UNAIDS”) due to increasing data showing the merits of starting
treatment earlier in the infection progression.
On a global scale, in 2007 the WHO and the Joint United Nations Programme on
HIV/AIDS (“Global AIDS Update”) issued guidelines focusing on provider-initiated HIV
testing and counseling to increase testing rates particularly in developing nations
(“Global AIDS Update”). During this time, the WHO and UNAIDS also announced
updated surveillance data indicating a leveling-off of HIV prevalence, a decline in new
infections and AIDS-related deaths. Domestically, AIDS-related deaths had surpassed the
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half-million mark since 1981 with an uptick in HIV incidence particularly among gay
men (“A Timeline of HIV/AIDS”).
In 2009, President Barack Obama called for the first National HIV/AIDS strategy,
launched the Global Health Initiative (GHI) and a major shift in international policy
occurred as the travel ban preventing HIV-positive people from entering the USA was
lifted (22 years after it was first enacted) (“What is the National HIV/AIDS Strategy?”).
Also, during this time, Congress altered the ban on using federal funds towards needle
exchange programs although the ban would be reinstated exactly one year later (“A
Timeline of HIV and AIDS”).
The following year saw the landmark passage of the Patient Protection and
Affordable Care Act (ACA) into law (“A Timeline of HIV and AIDS”), which provided
special protection for those with pre-existing conditions such as HIV when it comes to
purchasing healthcare insurance. Later in 2010, the White House released the inaugural
National HIV/AIDS Strategy for the United States. It is a 5-year plan that details the U.S.
plan to combat the HIV epidemic (includes priorities and strategic action steps with
measurable outcomes laid out) (“A Timeline of HIV and AIDS”). The strategic goals
outlined in the plan included: reduce infections, increase access to care and improve
health outcomes for PLWH, reduce HIV-related health disparities and health inequalities
and to achieve a more coordinated response to the epidemic. The strategy is scheduled to
be revisited and updated every 5 years with 2015 being the year of the next update
(“What is the National HIV/AIDS Strategy?”) (the 2015 update is discussed later in
chapter). During this time, the WHO released an updated version of its HIV treatment
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guidelines, advocating for earlier treatment by raising the CD4+ count indicator to 350
cells/mm3 from the previous 200 cells/mm3 (“New Progress and Guidance”).
In 2012, the U.S. Department of Health and Human Services (DHHS) revised its
treatment guidelines to now make ART recommended for all HIV-infected adults and
adolescents regardless of the CD4+ count or viral load measures (“Panel on Antiretroviral
Guidelines”). This in part due to research finding that early treatment of HIV positive
individuals had major benefits for them and for their HIV-negative partners. Later that
year, the FDA approved of an over the counter at-home HIV test with immediate results
and also approved the use of the drug Truvada as a pre-exposure prophylaxis (PrEP) to
reduce risk of HIV infection. UNAIDS estimated that at the end of 2012, that there were
over 1.2 million PLWH in the U.S. and 35.3 million PLWH worldwide (“A Timeline of
HIV and AIDS”). A study on 25 low and middle-income countries by UNAIDS shows
the rate of new HIV infections were cut in half and ART usage had increased by 63% in
those countries that were studied.
In 2013, UNAIDS called for a new set of targets for HIV treatment past 2015 and
created the 90-90-90 concept. By 2020, 90% of all PLWH will know their HIV status,
90% of all with a positive HIV diagnosis will have received ART and 90% of all people
receiving treatment will have successful viral load suppression which is when a person’s
viral load has reached a level low enough where the person can be deemed healthy and
their risk of transmission has been reduced (“90-90-90”). UNAIDS has estimated that
with the achievement of these goals by 2020, that we will be on the way to ending the
AIDS epidemic by 2030 which would have major health implications worldwide. They
believe that these goals are obtainable but only through strong principles grounded in
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“human rights, mutual respect and inclusion” (“90-90-90”). The concept will take a more
comprehensive approach to combating the epidemic, as in aside from the direct measures
(increasing access and use of ART), a concerted effort will be made to increase condom
programming, ending transmission via mother to child and increase PrEP usage. Also,
there will be an increase in harm reduction efforts for people who inject drugs and
voluntary male circumcision in high risk areas (“90-90-90”). The UN believes that for
these goals to be met that there much be a political will, utilization of advancing
technologies in testing and treatment, and system preparedness.
Also, in 2013, the WHO revised its guidelines for HIV treatment to now start
once the CD4+ count falls below 500 cell/mm3 from the previous 350 cells/mm3, (“A
Timeline of HIV and AIDS”). These new recommendations were in response to the
growing research showing the benefits of initiating treatment earlier in the infection
process. This is in accordance with the DHHS recommendations a few years earlier
which called for an even more aggressive treatment timeline, initiating it regardless of
CD4+ count (“A Timeline of HIV and AIDS”).
In 2014, the CDC reported that 1/3rd of PLWH were still receiving care as of 2011
and that the majority were no longer linked to care (“A Timeline of HIV and AIDS”).
The CDC also released a report documenting the gaps in HIV care and treatment among
Latino populations in the U.S. where less than half (44%) of Latinos diagnosed for HIV
had received ART and only 37% has achieved successful viral load suppression (“Gaps
in Care”). The following year, the CDC would release a report signifying that all
racial/ethnic minority groups experienced a disproportionate burden of HIV. The report
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also named men who have sex with men (MSM), young adults and people who live in the
southern region of the U.S. as particularly vulnerable populations.
In 2015, Indiana state health officials announced an outbreak of HIV in the
southeastern, mainly rural portion of the state (“A Timeline of HIV and AIDS”). The
outbreak brought to light two major underlying public health issues in rural settings, the
spread of HIV and an increase in IDU (“A Timeline of HIV and AIDS”). During this
time, the White House released the National HIV/AIDS Strategy: Updated to 2020
(“What is the National HIV/AIDS Strategy?”) which reflected on the accomplishments
(and lessons learned) from the 2010 version and provided updated strategies/scientific
advancements in combating HIV. Among the changes in the new version, there are 10
new quantitative indicators to better monitor progress and 4 new goals including
universal viral suppression and full access to PrEP (“New Guidance and Progress”). The
CDC reported that annual HIV diagnoses in the U.S. had dropped 19% from 2005-2014.
Although the rates did increase among Latino gay/bisexual men (+24%) and black
gay/bisexual men (+22%), it was also reported that only 1 out of 5 sexually active high
schoolers were tested for HIV and half of young Americans who have HIV are aware of
their status (“Panel on Antiretroviral Guidelines”).
In 2016, the DHHS released new guidelines for state, local, tribal, and territorial
health departments so that they can request permission to use federal funds towards
syringe service programs (“A Timeline of HIV and AIDS”). The United Nations (UN)
held a general assembly meeting in New York that same year where all the member states
adopted a new political pledge to end the AIDS epidemic. Medically, the first organ
donation from an HIV-positive donor to an HIV-positive recipient occurred in the U.S.
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Also, in the past few years the federal ban against men donating blood who had sex with
other men had been altered to allow men who had not had sex with men within the past
12 months. Pharmacy researchers also noted that the FDA-approved antiretroviral drug
Truvada was effective in reducing the risk of HIV infection but only if women took it
daily and twice a week for men (“A Timeline of HIV and AIDS”).
According to WHO (“A Timeline of HIV and AIDS”) PLWH are living longer
and healthier lives than ever before with the advancement in ART and major progress has
been made in eliminating mother to child transmission. Eight out of every 10 pregnant
women living with HIV were on ART. A major development in the global HIV strategy
was the midpoint assessment of the UNAIDS 90-90-90 targets. The UNAIDS report on
the work done since 2015 to achieve the goals noted the progress made and the work still
needed to be done (“A Timeline of HIV and AIDS”). As of 2017, an estimated 70%
globally knew their HIV status and among those who knew their status 77% were on
treatment. Of those who were on treatment, approximately 82% had successful viral load
suppression (“Ending AIDS”).
Treatment coverage increased from 17.8 million in 2015 to 19.5 million in 2016
and the increased rate of additional people on ART annually puts coverage on pace to
meet the UN General Assembly’s target of 30 million PLWH on treatment by 2020
(“Press Release”). Seven countries had already achieved 90% of PLWH knowing their
status and an additional 16 countries are near the target (between 85%-89% achieved)
(“Press Release”). UNAIDS noted in its report that recent data indicated knowledge of
HIV status had improved greatly over the past decade and will need to continue to
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improve as does linkage to care after diagnosis if the targets are to be reached by 2020 as
the world tries to end the HIV epidemic soon (“Press Release”).
The historical timeline of HIV has shown that domestically and internationally,
the strategy to combat this epidemic has changed greatly over the years but has become
more collaborative and global in the process. The global collaboration will need to
continue in the present and future if the goal is to further contain and eventually,
eliminate the spread of HIV particularly in high-risk areas. History has shown that the
epidemic can be halted through collective prevention strategies and
technological/pharmaceutical advancements in the public health and medical fields on a
more global scale.
2.2 Epidemiology of HIV Nationally and Globally
The state of HIV domestically and internationally has been shaped by many
different policies and events over the years. HIV/AIDS while initially a domestic issue
has since expanded to become a worldwide pandemic, currently affecting nearly 40
million people- although these numbers would be higher if not for global preventative
measures (“Ending AIDS”) The skyrocketing number of PLWH since the 1980s is
attributed in large part to the vast improvement and expanding distribution of ART
(Fettig et al.). There are over 17 million PLWH on ART across the globe as of 2015,
more than double the number just 5 years prior in 2010 (“Ending AIDS”).
2.2.1 National Statistics
As of 2014, there were over 1 million PLWH in the United States with most of
them concentrated in distinct geographical regions. There were an estimated 37,600 new
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infections in the U.S. at the end of 2014, with half of them occurring in the South where
the epidemic has shifted towards in recent years (“HIV in the United States”). There was
a drop in new infections by 18% from 2008 to 2016 (45,700), with the sharpest decline
coming among IDU at 56% The most recent count of new HIV infections was in 2016
(n=39,782, which is a slight uptick from 2014). Among new infections, gay/bisexual men
made up 67% of incident cases, specifically African American gay/bisexual men. IDU
accounted for 9% of the new HIV diagnoses in 2016 and accounted for 12% of diagnoses
among women (“A timeline of HIV and AIDS”).
In 2014, the CDC reported that 49% of adults and adolescents being treated for
HIV had successful viral load suppression (“HIV Surveillance Report 2016”). All age
groups saw a decrease in rate of HIV diagnoses except for the 25-29 age group which
saw an increase as did rates for Asians and American Indians/Alaskan Natives while rates
from African Americans and Whites decreased and rates remained stable for Latinos
(HIV Surveillance Report). New HIV infections by modes of transmission decreased
between 2011-2015 including IDU and MSM. In addition to IDU, non-intravenous drug
use is also associated with spread of HIV as it promotes sexual transmission.
The U.S. has seen a recent steady increase in HIV among rural communities
across the country especially in the epicenter of the Deep South where HIV rates in
smaller metropolitan and rural areas were the highest (“HIV/AIDS in Rural America”).
The prevalence rate of PLWH in non-metropolitan areas is 99.5 per 100,000 people in the
South, with African Americans accounting for 50% of these prevalent cases. As the rate
of HIV increases in rural America, as does the burden associated with HIV treatment for
rural residents and the healthcare system that serves them. Individuals in rural areas are

23

less likely to have healthcare insurance to cover potential costs of HIV treatment
compared to those in urban areas. This is a major issue in rural areas, as people with HIV
there are less likely to get tested due to cost or lack of access to testing facilities
compared to those in urban areas and once they are diagnosed, they tend to be at a more
advanced stage (“HIV/AIDS in Rural America”).
A study done on drive-time to HIV care facilities in 3 states in the Midwest
(Kansas, Missouri and Nebraska) found that people with HIV in rural areas had to drive
an additional 45 minutes to their nearest HIV facility compared to PLWH in urban areas
(Oppong). Due to the small population size and interconnectedness of rural communities,
there may be issues of confidentiality which may “keep PLWH from seeking medical,
support or social services” in their local community for fear of stigma (Oppong). These
barriers are major concerns in the changing landscape of HIV nationally.
Overall, while the U.S. has lower rates of HIV prevalence compared to other
nations, the areas that do have a high prevalence are typically in areas saddled with
poverty (Pellowski). The CDC has reported that HIV prevalence rates tend to be highest
among those who are either at or below the poverty level (“Characteristics Associated
with HIV”). This is most relevant in the south where poverty, income inequality,
residential racial segregation, and poorer health outcomes are all major concerns.
2.2.2 Southern U.S. Statistics
Eight of the top 10 states for annual HIV incidence rates are located in the south
and over 40% of PLWH reside in a southern state, the highest rate among any region in
the U.S. Even more alarming is that almost half of the deaths among PLWH in the U.S.
come from the South. As of 2015, the rate per 100,000 of HIV diagnoses was16.8 in the
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South, the highest of any U.S. Census region (Williams). The states with the highest rate
of HIV diagnoses per 100,000 were Louisiana (29.2) followed closely by Georgia (28.3)
and Florida (27.9). These troubling rates are due in large part to previously mentioned
factors (high poverty and poorer health outcomes) along with higher than average rates of
people without health insurance, lower levels of education, and poorer social capital (lack
of trust, higher rates of racism and stigma still associated with STIs) (P.B. Williams).
Another major barrier in stemming the HIV epidemic in the South is that there are fewer
people living in the South that are aware of their HIV status compared to the other
regions across the U.S. (Williams).
Although most new HIV diagnoses are in urban areas, the south has the highest
rates of new HIV diagnoses in suburban and rural areas (Reif). A study done by Weisman
(2015) found that those in rural areas of the south were more likely to have a positive
AIDS diagnosis within 1 year of HIV infection compared to those in urban areas in the
region. This is likely due in large part to the lower retention of HIV treatment associated
with rurality along with worse spatial access to HIV care (both in volume of facilities and
drive-time to facilities) - factors that can lead to worse rates of viral suppression (Reif).
The findings in this study were supported by a CDC report; approximately 75% of people
diagnosed were linked to HIV care within 1 month but half of the states across the South
fell below that rate (“HIV in the United States”). This evidence coupled with the CDC
placing 10 of the 16 states in the South in the top quartile for lifetime risk of being
diagnosed for HIV shows the complexities of the epidemic in the South (Williams).
Like many other diseases, there are significant racial/ethnic disparities in HIV
diagnoses. In the south, 55% of HIV diagnoses are among African Americans, the single
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highest proportion for any race in the region (“HIV in the United States”). This disparity
may reflect a lack of access to primary healthcare among African Americans, high rates
of uninsurance, a disproportionate burden of IDU and other HIV-related risk factors, and
a lack of trust in healthcare due to previous acts of injustice (Pellowski). Stigma towards
HIV is also particularly high within African American communities, even among
adolescents. An even more stigmatized group in the South is the MSM/bisexual African
American community, where 60% of all black MSM diagnosed with HIV across the
United States in 2014 resided (P.B. Williams).
2.2.3 Northeastern U.S. Statistics
Although the South may be home to the highest percentage of new HIV
diagnoses, the Northeast still has the highest prevalence rate of people living with
diagnosed HIV infection at 419.5 per 100,000 (“HIV in the United States”) followed by
the South at a rate of 352.5 per 100,000.
In terms of HIV infection progressing to AIDS, the Northeast has the second
highest rate of annual AIDS diagnoses (accounts for 18% of U.S. total in 2015) and HIVrelated deaths (19% of U.S. total) (“HIV in the United States”), although both are far
below the rates in the South (53% for both, respectively).
Rates of new diagnoses among African Americans in the Northeast are similar to
those in the South (“U.S. Statistics”). In 2015, the Northeast also had the second highest
rate of new HIV diagnoses among Hispanics/Latinos (28%), behind only the Western
region of the United States.
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2.2.4 Midwestern U.S. Statistics
The rate of HIV diagnoses per 100,000 was lowest in the Midwest among the four
Census regions at 7.6 per 100,000, with African Americans accounting for 47% of those
diagnoses (“HIV in the United States”). In terms of HIV progressing to AIDS, the
Midwest has the lowest rates of any region for annual AIDS diagnoses (accounts for 12%
of the U.S. total) and among AIDS-related deaths (11% of the U.S. total) (CDC, “HIV in
the United States”).
Even though the rates in the Midwest are lowest overall (only one state in the
region has a cumulative rate greater than 10 cases per 100,000), one area of major
concern is the high rates of new HIV diagnoses in rural areas in the Midwest (20%,
which is the second highest among the four regions). These troubling numbers are
compounded by the farther distances to healthcare facilities that provide HIV care
services in rural areas compared to urban areas and the increased stigma associated with
HIV among rural communities (Oppong).
2.2.5 Western U.S. Statistics
While the Western region has a higher rate per 100,000 of HIV diagnoses (9.8)
and prevalence (244.2) than the Midwest, it has the lowest rate of African Americans
diagnosed with HIV at just 18%. As of 2015, the predominant race diagnosed with HIV
in the west is Hispanic/Latino (38%) followed by white (34%). Along with the higher
prevalence of HIV in the West, there is a higher AIDS-related mortality rate (17%)
compared to the Midwest. The West has the second highest rate of new AIDS diagnoses,
behind only the Southern region of the United States.
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California and Arizona both have higher rates of HIV diagnosis than the rest of
the region although the highest rate belongs to Nevada (21.4 per 100,000). This may be
due to the high rates of co-morbidities (3rd highest rate in the country for syphilis) and
high rates of HIV transmission through MSM (“Nevada”). It is of interest to note when
looking at HIV transmission by gender, rates of HIV transmission by intravenous drug
use were consistently nearing 25% among females (while intravenous drug use among
males were consistently <10%).
2.2.6 Africa
Globally, the highest proportion of PLWH as well as new HIV diagnoses reside in
the continent of Africa. The largest gain of ART coverage also came from Africa, mainly
in the south and eastern regions. There has been much investment internationally in
combating HIV in Africa with mixed but encouraging results.
HIV surveillance across the continent, while improving, is still quite poor, so
most current HIV figures come from statistical (vs. direct) estimates. The
epidemiological trends of HIV differ based on the region of focus. Sub-Saharan Africa is
showing sustained trends of lowering estimated rates of HIV infection and decreased
AIDS-related mortality rates along with a higher prevalence of PLWH (estimated 20.8
million in 2000 to an estimated 25 million as of 2012) (“Global Report 2013”). North
Africa on the other hand has increasing rates of HIV infection and AIDS-related
mortality rates along with higher rates of PLWH (estimated 260,000 as of 2012)
(“Progress Report 2011”). However, even with the opposite trends of HIV, the incidence
and prevalence of HIV is still much higher in Sub-Saharan Africa compared to the rest of
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the continent. The higher rates of PLWH is in large part due to the increased access and
use of ART across the continent. Also contributing to the lower rates of HIV incidence
and prevalence in North Africa is high rates of male circumcision, which has been found
to decrease risk of HIV (Abu-Raddad 54). There have been concerted efforts to promote
voluntary male circumcision in Sub-Saharan Africa to stem HIV incidence in the region.
However, even with the focus on HIV preventative measures, when looking at the top 25
nations in terms of adult population living with HIV, Africa includes 23 of the top 25
nations as of 2017, as per UNAIDS. Further complicating the issue is that as of 2017,
approximately 76% of PLWH knew their status in western and northern Africa whereas
only 42% of PLWH knew their status in central and eastern Africa (“Ending AIDS”).
The common mode of HIV transmission across Africa is unprotected intercourse,
both heterosexual and MSM. Intravenous drug use (IDU) is also a key mode of
transmission in Northern Africa but not the Sub-Saharan regions. Opium and heroin
usage rates are higher in Northern Africa than anywhere in the world aside from the
Middle East, such as in Libya where an estimated 90% of HIV cases can be attributed to
IDU. Another troubling mode of transmission found more in Sub-Saharan Africa than
other areas is mother-to-child transmission. Although using ART treatment limits this
type of transmission to only 1% probability, getting access to ART and HIV testing is
still not up to par in this region (“Global Report 2013”). There is progress being made
however from 1995-2010, over 86% of children susceptible to HIV infection through
their mother who did not develop the disease thanks to ART. Still, 88% of all children
under the age of 15 with HIV still come from this region due to poor access to HIV care
and other risk factors (Fettig et al.).
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There has been an overall concerted effort in increasing access to ART in SubSaharan Africa and as a result, the AIDS-related mortality has decreased annually since
the early 2000s. This is not the case in North Africa where AIDS-related mortality rates
have increased during the same time in part due to poor access and use of ART. As of
2012, only 11% of those who needed ART treatment, actually received it in North Africa
(“Ending AIDS”).
An area where HIV surveillance is lacking due to social norms and stigmas deals
with diagnosing HIV via MSM transmission. What little data there is, shows higher rates
of HIV among MSM compared to the rest of the general population across the continent
of Africa (Abu-Raddad).
2.2.7 Asia
After Africa, the continent of Asia has the second largest burden of HIV globally.
Over 5.2 million PLWH as of 2016 and rising due to longer life spans from ART
although HIV transmission rates have seen a decline in recent years (Fettig et al. 1). India
and China have the largest burden of HIV in Asia with 2.1 million and 780,000 PLWH as
of 2012, respectively. Adding the PLWH from Indonesia and that constitutes threequarters of the total number of PLWH in Asia. Taking into account population size
however, India only has a prevalence rate of 0.3%, lower than many other countries in
Asia such as Cambodia (0.85) (“Ending AIDS”). The country with the highest HIV
prevalence is Thailand at 1.1%. Unlike other countries in Asia where the epidemic is
mostly concentrated in specific key populations, the epidemic in Thailand is more
generalized among the population.
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Overall, approximately 71% of PLWH in Asia know their status as of 2017 and of
those who do, two-thirds are on HIV treatment. Domestic efforts in HIV/AIDS response
throughout Asia has increased greatly over the past decade to the point where of those
who are in treatment, over 80% have successful viral load suppression (“Ending AIDS”).
In terms of transmission, MSM accounts for 18% of new HIV infections
particularly in urban cities such as Bangkok and Yangon (Fettig et al.). It is reported that
this demographic tends to skew younger due to lower rates of HIV testing and condom
use among MSM under the age of 25. Injection drug use is another key mode of
transmission across the continent. Stringent policing and incarceration of intravenous
drug use along with poor drug treatment programs in prisons are all major factors in the
high rate of HIV in this category.
A highly susceptible population that is underserved and under researched is the
transgender population of Asia. HIV prevalence among transgender populations is higher
than rates among MSM in many areas across Asia (“Asia and the Pacific”) such as in the
urban centers of India (Delhi, Mumbai) and Cambodia. The transgender population is as
stigmatized and discriminated against as any high-risk HIV group in Asia. These barriers
are key factors in rampant HIV rates among this population and makes testing and
treatment more difficult. The current level of AIDS healthcare-related resources
throughout the continent are estimated by UNAIDS to be 37% below the needed levels
for Asia to reach the 90-90-90 fast track goals by 2020 (“Global Report 2013”), in large
part to the decrease in international investment in the cause as funds are being focused on
other regions of the world. So more global investment and time is needed to better
combat the epidemic in Asia.
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2.2.8 Latin America and the Caribbean
As of 2017, 81% of PLWH in Latin America and 64% of PLWH in the Caribbean
knew their HIV status. Of those, 72% in Latin America and 81% in the Caribbean were
on treatment and among those in treatment, 79% and 67% had achieved viral load
suppression in those two regions (“Ending AIDS”).
However, the efforts to treat HIV in Latin America continue to be hampered due
to high rates in late diagnosis as 1/3rd of people diagnosed are done so at advanced stages.
The number of new infections in Latin America and the Caribbean remained stable this
past year at around 100,000 and 17,000, respectively (“Ending AIDS”).
In terms of transmission, the highest prevalence of HIV in Latin America is
among MSM with 9 of the 14 countries in the region having rates over 10% (Fettig et
al.). Treatment adherence in the region was also worse among female sex workers, IDU
and MSM compared to the general population. The Caribbean has an even larger HIV
issue among MSM, as over 25% of them are infected with HIV, the highest prevalence in
the world for this demographic. Positive developments in the Caribbean stem from
increasing rates of pregnant women with HIV receiving treatment (79%) the decline of
AIDS-related deaths in both regions. More investment in HIV care is needed in key
subpopulations throughout the region if the HIV epidemic is to be controlled, especially
among vulnerable populations such as women who make up a larger proportion of
PLWH in these two regions than anywhere else in the world at 60% (Fettig et al.).
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2.2.9 Europe
Eastern and Western Europe have vastly different outlooks when it comes to the
HIV epidemic. While Western Europe has seen decreased rates of AIDS-related mortality
over the past decade (due in large part to better access to ART), Eastern Europe has seen
increased rates in AIDS-related mortality (“Ending AIDS”). Russia has seen an increase
in HIV infection due largely to the major IDU problems in the region. Approximately
80% of HIV infections in Russia are among persons with IDU (Fettig et al.). The
epidemiology of HIV in Western Europe mirrors that of other higher-income regions
such as North America where with the advent of ART, rates of PLWH has increased in
Western Europe to over 800,000 as of 2012 and HIV prevalence is stagnant at 0.2%
(“Ending AIDS”). As with North America and other regions with a large immigrant
population, Western Europe has a high proportion of its HIV cases coming from ethnic
minority populations, specifically Sub-Saharan Africa which accounts for a large portion
of AIDS cases (Fettig et al.).
Eastern Europe accounts for approximately 80% of the annual new HIV
diagnoses and less than 1/3rd of PLWH were currently on ART (“Progress Report 2011”).
Europe has struggled with raising the rates of early diagnosis, as approximately 50% are
diagnosed at late (CD4+ count below 350 cells/mm3) and or advanced stage (CD4+ count
below 200 cells/mm3) (“Progress Report 2011”). Coupled with the fact that a quarter of
PLWH in the region are unaware of their status, Europe still has challenges in combating
the HIV epidemic, moving forward.
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2.2.10 Canada
Canada has seen fluctuating rates of HIV prevalence rates over the past 30 years
with rates increasing in the 1980s, followed by a dip in the 1990s and then a gradual
increase since then. From 2011-2014, the rates of PLWH in Canada have increased by
10% (“The Epidemiology of HIV”). The estimated prevalence rate in Canada at the end
of 2014 was 212 per 100,000. Among PLWH, the majority of them are men (78%),
specifically MSM (53%). The remaining proportion of PLWH contracted the disease
either through IDU or heterosexual contact and the main mode of transmission differs by
region. Health officials in Canada believe that 1 out of every 5 with HIV are undiagnosed
in general that 17% of intravenous drug users have HIV (“The Epidemiology of HIV”).
While the rate of new infections remains stable, a positive note is that the rate of
AIDS-related deaths has decreased in the past decade due to new antiretroviral therapy
HIV treatment (“The Epidemiology of HIV”).
2.3 Biology of HIV
A major component in understanding the plight of HIV globally is to understand
the biological mechanisms of the retrovirus, its origins, how it spreads and the
mechanisms behind its treatment. By better understanding the retrovirus itself,
researchers have been able to build prevention and containment strategies which have had
success but due to the complexity of the disease. There is still have much more to learn
and research as HIV continues to spread despite major advancements in medicine and
technology regarding disease research.
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The HIV retrovirus originally started as a zoonotic virus called simian
immunodeficiency virus (SIV) (Maartens 258) and was transmitted by primates in Africa
to humans over 100 years ago (Sharp 3). HIV-1 and HIV-2 are the two main types of
HIV. HIV-1 is transmitted from apes and is the more transmittable, pandemic form of
HIV (Sharp). HIV-2 infections are found almost exclusively in West Africa through
sooty mangabey monkey transmission (Maartens 258). HIV-2 infected individuals tend to
have lower viral loads which would explain the lower transmission rates when compared
to HIV-1 (HIV-2 prevalence rates in general are on the decline (Maartens). HIV-1 has
four different group lines- M, N, O and P. Groups M, N and O all come from
chimpanzees while group P comes from gorillas (Maartens). Group O was found in 1990
is confined to central-west Africa and accounts for approximately 1% of HIV-1
infections, Group N was found in 1998 is even more isolated, having only been positively
diagnosed in 13 patients, all living in Cameroon (Vallari). As of 2011, Group P was
found in 2009 and has only been positive transmitted to two patients, both also from
Cameroon although one lived in France at the time of diagnosis (Sharp). Group M is the
first group to have been discovered and is by far the most impactful as it is the HIV-1
group identified as causing the HIV pandemic that has infected millions of people and
still plagues the world today (Maartens).
There are nine group M subtypes- A-D, F-H, J and K (Maartens). A crosssectional study done looking at worldwide HIV infection data from 2004-2007 found that
of the different subtypes, C is the most transmittable. Subtype C accounted for 48% of
infections, mostly in Africa and India (“Ending AIDS”). Subtype A which, is found in
Europe and East Africa along with subtype B which is found in the Americas, Australia
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and Europe, accounted for 12% and 11% of global infections, respectively (“Ending
AIDS”). HIV-2 has eight different group lines, A-H. However only two groups, A and B,
have been positively diagnosed in more than one individual (Sharp 11).
2.3.1 Transmission
Over the past 30 years, while there have been many false claims of how HIV
spread (insect bites, touching, sharing household objects with someone infected), there
have been multiple methods of HIV transmission have been confirmed: sexual
intercourse (heterosexual or men having sex with men-MSM), HIV-tainted blood
transfusions, shared intravenous drug equipment, materno-fetal-child paths (in utero,
breast milk feeding), and through organ transplantation. It has been noted that male
circumcision status (Hemelaar) can either increase or reduce the risk of HIV transmission
via sexual intercourse.
The different methods of transmission come with unique secondary
complications/illnesses such as co-infections like hepatitis B and C (Lucas). The chief
factor in determining the likelihood of HIV transmission is the viral load of HIV blood in
the infected individual (Quinn) with the viral load being highest immediately following
infection (Lucas). This is particularly an issue when dealing with acute (primary stage)
HIV infection where the virus is replicating rapidly while the individual is asymptomatic.
Sexual intercourse/contact during this time frame has been central in spreading the HIV
infection (Cohen). Since the viral load levels are of such importance, researchers have
shaped treatment around the individual achieving successful viral load suppression which
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is where the levels are at such a low level that the person is deemed healthy and their risk
of HVI transmission has been reduced.
2.3.2 Pathogenesis
Once HIV has infected the human host (stage 1), its main target are white blood
cells, specifically a cluster of differentiation 4 (CD4) +T lymphocytes, which are
important in fighting off infection. The higher the CD4 count in the body, the better it can
defend against infection so as the HIV retrovirus targets, infects, replicates within and
destroys CD4+T cells, it weakens the body’s ability to fight of infection. Specifically, the
cell-mediated immunity would be severely weakened as the HIV retrovirus spreads
throughout the body. The virus will also target non-CD4+ cells such as endothelial cells,
enterocytes, kidney tubules, cardiac muscles but to a much lesser extent (Lucas). This is
also the phase of the HIV process where transmission to others is at its highest risk levels.
Eventually the HIV retrovirus will slow down its replication and CD4+ destruction
process (stage 2) but is still active within the body and transmission of HIV to others is
still possible. Normal CD4 counts range between 500-1500 cells per cubic millimeter and
if the count drops to below 200 cells due to HIV infection, the most advanced form of
HIV infection-acquired immunodeficiency syndrome (AIDS), is diagnosed (stage 3).
Aside from CD4+ count depletion, another critical effect the HIV infection has on
the body is the role it plays in increased innate and adaptive immune activation.
Regardless of the patient undergoing ART or going untreated, body organ functions will
be affected in some capacity due to raised levels of inflammatory markers in the body
fluids (Lucas). The longer the HIV infection goes untreated, the higher the likelihood of
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chronic immune activation. This can have serious implications in cell replication and
communication. Dendritic cells infected with HIV, will continue to secrete interferonalpha cells which leads to low levels of HIV replication (this is even possible during ART
treatment). The gut mucosa becomes weakened against gut bacteria due to depleted
helper T-cell levels which triggers further acute and chronic inflammation throughout the
rest of the body (Lucas).
2.3.3 Antiretroviral therapy
Prior to antiretroviral therapy (ART), the weakened cell-mediated immunity
would cause major problems for those infected with HIV, especially in those whose HIV
advanced to AIDS (Lucas). Now, those infected with HIV have much long-life
expectancies and better quality of living. The CD4 count threshold that has been
recommended as a guideline before starting a patient on ART has shifted over the years.
The WHO has updated its recommendations several times for when to start ART
treatment based on CD4+ counts from an original recommendation of <200 cells/mm3 to
<350cells/mm3 in 2006 (“Antiretroviral Therapy”). In 2013, there was another
recommendation added regarding key high-risk populations. People infected with both
HIV and either Tuberculosis or Hepatitis B were recommended to undergo ART once
their CD4+ count <500 cells/mm3. This was also recommended for pregnant and
breastfeeding women infected with HIV as well as children under the age of 5
(“Consolidated Guidelines 40”).
It is now recommended for all people infected with HIV to begin ART regardless
of CD4+ count (Hofman). This is due to research showing the benefit of starting ART
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earlier on in the HIV infection process as opposed to waiting until the CD4 count dipped
below a specific threshold. This recommendation also takes into account the safer and
less risk adverse class of drugs being used in treatment. A drawback of ART until now
was pathological toxicity especially in the liver that came with prolonged use (“Panel on
Antiretroviral Guidelines”) but with the new class of drugs in place, scientists feel
comfortable to recommend earlier ART treatment.
2.3.4 Prevention
Since the HIV/AIDS epidemic came into the global spotlight, there has been a
major urgency to understand the disease, from its origins to how it is contracted and
transmitted, how to treat it and methods of prevention against initial
contraction/transmission. In terms of preventative measures, a collection of interventions
and measures are needed to stem an HIV epidemic. Prevention measures range from
using protection (e.g., condoms) during intercourse, not partaking in IDU or not sharing
needles if you do, getting tested before intercourse (both you and your partner), as well as
more voluntary male circumcision and even taking pre-exposure prophylaxis (PrEP) if
you are considered a high risk for HIV (“ Consolidated Guidelines” 64). A relatively
recent development in stemming the HIV epidemic (and the IDU epidemic as well) are
the community-based needle exchange programs (NEPs). NEPs are set up to provide
access to sterile needles and syringes at no cost, as well as to provide a safe drop off spot
for already used needles. Studies done have shown the effectiveness of these types of
programs in reducing the spread of Hepatitis C infection. Some of these programs also
provide access to supplementary services such as STD screening, education on safe
needle practices, and prevention materials (e.g., alcohol swabs, condoms) (Castaneda).
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In terms of preventing HIV transmission, many of the same measures are
recommended including frequent HIV testing, not using and/or sharing dirty needles, and
adherence to ART, which has been a major development in the treatment and increased
quality of life for PLWH. Adherence to ART treatment after has shown major
developments in reducing HIV transmission (Vallari) among all groups of PLWH.
Particularly, ART has been seen as a major preventive measure in reducing risk of
transmission from mother-to-child. Without any intervention, there is roughly a 25% risk
of HIV transmission to the child at birth, but the risk is greatly mitigated if the mother
undergoes ART treatment, most preferably, after the first trimester (Sharp).
2.4. Expanding Upon Importance of Research
HIV rates have continued to decrease overall in the U.S., as measures have been
taken to stem HIV transmission (safe sex practices, needle exchange programs, increased
testing efforts) and raise HIV treatment coverage (advancement in ART and related
access to treatment). Many of the aforementioned programs apply explicitly to HIV
prevention in urban areas. However, HIV in rural settings (where surveillance data is not
always available) has increased over the past decade due to major barriers related to drug
use, healthcare accessibility, and socioeconomic deprivation, and has become a major
public health concern (Pellowski).
The U.S. is largest funder of HIV programs in the world (“Global Report 2013”),
leading to many HIV-related programs and research studies, most exclusively limited to
urban areas. There are far fewer studies done in rural areas. Until recently, HIV had been
deemed a predominantly urban issue due to its infectious nature, and higher prevalence in
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urban areas (“HIV in the United States”). HIV in urban settings have decreased while
HIV in previously considered low prevalence areas have silently gone up in recent years.
The lack of readily available surveillance data in rural settings coupled with high rates of
drug use, high rates of poverty and lower education levels have led to HIV in rural
settings becoming a public health crisis in this country.
Research on HIV prevention, treatment and survivorship has been focused on
PLWH in predominantly urban areas. The major disconnect is that the research has led to
policies and interventions that are not encompassing to all PLWH, as persons living in
urban areas have vastly different experiences than those living in rural area (Oppong).
PLWH in rural areas have major barriers such as access to transportation, availability of
HIV related services and healthcare costs due to lower rates of insurance coverage
compared to their urban counterparts.
Also, while both populations face stigma and judgment issues, those in urban
settings tend to have greater access to additional HIV related resources such as support
groups and tend to face a less intense stigma about their condition compared to those in
rural settings (P.B. Williams). Rural settings are more likely to hold stereotypical views
about HIV (Pellowski). People in those areas also tend to have less knowledge about
HIV/AIDS such as how HIV it is contracted and spread (P.B. Williams) which is not
faced as often by PLWHA in urban communities.
The textbook example of the culmination of all these factors is in the HIV
epidemic observed in rural Indiana in 2015. There were 190 cases of HIV in Scott
County, Indiana a largely rural community, in 2015 (Ungar). The outbreak was sparked
by an opioid epidemic that has been quietly plaguing the area (like other rural
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communities) for years. In addition, the county had high rates of poverty and dirty needle
sharing was prevalent. The clean needle exchange program (NEPs) used by many states
to stem needle sharing, was banned in Indiana at the time. Scott County had only 1 HIV
testing site prior to the outbreak- A Planned Parenthood Clinic was defunded and closed
in 2013, leaving the area with no free source of testing. This setting had many critical
features needed for an outbreak- low SES (poverty), no access to testing and high IDU
use (risky behavior). This outbreak served as a warning that the epidemic was no longer
an urban problem but a national one (Ungar). As the current mindset starts to shift, new
studies need to be done taking into account all factors that affect HIV including social
and structural factors in play.
These events have put an even greater emphasis on the need for studies showing
the full picture of HIV in America from identifying areas with poor access to care,
updating HIV prevalence in un-reported areas to get a better idea of the HIV burden and a
closer look at the usage of HIV testing among all population groups.
2.5 Previous Studies and Rationale for Research
The importance of this project comes into perspective when reviewing the
previous literature or lack thereof, particularly in recent history (past 5 to 10 years). More
research is needed to examine access to HIV-related resources in rural areas, estimate
HIV prevalence statistics in rural areas (and other geographic regions with
sparse/suppressed HIV data), and explore different disparities in HIV testing rates among
various vulnerable subpopulations.
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2.5.1 Spatial Access to HIV-Related Resources
There are only a handful of studies that discuss access to HIV-related resources as
a factor in the HIV epidemic. Pellowski et. al. discusses many different general barriers
to care for PLWH in rural areas, a key factor being suboptimal access to HIV care. It
goes into more detail than most on discussing the pitfalls involved in having access to
quality HIV care based on “psychological, social, and economic factors”. A major topic
brought up in previous literature deals with how soon after being infected with HIV, does
the person both get tested for and received HIV treatment (Pellowski).
A study done by Weissman et. al., discussed how rurality was identified as a risk
factor for late HIV diagnosis in South Carolina. Rural areas in the South, and to an
extent, rural areas across the nation, face limited access to HIV care based on density and
location of services, as well as stigma that may prevent people from using the resources
available to them. Among over 4,000 new diagnoses of HIV between 2001 and 2005 in
South Carolina, a quarter resided in rural areas. Among those individuals, it was found
that almost half of them were diagnosed late, which greatly impacts their prognosis. A
late diagnosis was determined after assessing the CD4+T-cell count at time of diagnosis.
It was found that people from rural SC had on average a lower CD4+T cell count than
those from urban areas.
There have been no publications within the past five years examining spatial
access to HIV-related resources nationally, nor have there been any updates to previous
studies looking at spatial access to care focusing on specific regions or subpopulations.
Focusing on spatial access to HIV-service providers in Atlanta, GA, Dasgupta et.al.
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developed a tool to measure proximity to services and provider related traits in a single
measure. In their study, also used road distance measures between a provider and a
population cluster (in this case, a census tract centroid) in assessing spatial accessibility.
We will be using similar methods in assessing accessibility of HIV-testing resources for
Aim 1. A second study by Ganapati et.al, in Miami, FL. delved into a zip-code level
investigation of spatial access to HIV service providers. While both of these studies have
merit, and provide groundwork to build upon, they focus solely on a single urban setting
and are not representative of rural communities. A more comprehensive research is
needed to understand the present state of HIV testing accessibility for PLWHA in order
to identify areas for future interventions and strategies/policies to
2.5.2 Small Area Estimation
There are numerous studies done on small area estimation (SAE) methodology
and the application of SAE to real world outcomes ranging from tobacco use to obesity
prevalence, among others. Barker et.al, estimates diabetes incidence and is of particular
interest given it utilizes individual-level BRFSS data, which is the primary data set for
the 3rd aim of this project. It takes work done from a previous study done by Cadwell,
2005 where they looked at diabetes prevalence and alters it to estimate county-level
diabetes incidence in the U.S. Barker et. al. takes a different approach than ours in that it
is a unit-level model-based approach, whereas our project utilizes an area-level modelbased approach. It does take a similar spatial approach, however (i.e., accounts for region
in the SAE model). However, most studies utilize a unit-level approach and very few take
a strictly area-level model-based approach. The previously mentioned Cadwell, 2005
article on diabetes prevalence does use the same Poisson distribution for modeling as
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ours while the Barker study used a binomial distribution. Both articles provided good
insight into general differences between small area estimation models and background
information on the topic.
Among the scarce number of recent papers that utilize an area-level model-based
approach, an article done by Esteban, 2012 looked into different variations of area-level
models and examined which was most accurate at estimating poverty in Spain. The paper
made a strong argument for why unit-level based model approaches were less feasible to
do for this scenario and that area-level models were much easier to apply given the nature
of the data available for use. The article also introduced a time component to borrow
further strength for the model. We lean on this rationale as well, as only area-level
information is publicly available to estimate HIV outcomes at the county level for our
study. An article by Trevisani, 2017 also discusses the merits of different model
specifications for estimating small area counts (including Poisson modeling, which is
utilized in our project) and provided useful comparisons between the different variations
of SAE methodologies. Using solely area-level covariates and an innovative spatial
modeling approach, we can estimate HIV burden for those areas previously unaccounted
for in publicly available statistics, particularly the Western region of the U.S.
2.5.3 HIV Testing rates using BRFSS
There have been quite a few studies done on HIV testing in the past X years, but
only a few studies have utilized the Behavioral Risk Factor Surveillance System (BRFSS)
as a primary data source. These studies vary in terms of scope, ranging from temporal
trends in a single state (Ansa) to nationwide testing rates for a limited age bracket (Ford)
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to HIV testing pre-and post a particularly policy change, (Gaines) but none have looked
at HIV testing rates across the country for all eligible age groups over a length of time.
Still, there is valuable information and methodologies to be taken away from
these differing studies. The Ansa, 2016 study focuses on exploring trends among HIV
testing rates in adults from 2011-2015 in Georgia. This study provided descriptive
statistics concerning overall HIV rates across the state and its subgroups. It also looked at
time trends for HIV testing and provided suggestions on how to stem transmission in
Georgia based on the results. Our study will incorporate much of what was done in this
study on a national scale, over a similar time frame.
The Ford, 2015 study also focuses on temporal trends in HIV testing but focused
only among U.S. older adults (50–64 years of age) before and after the release of CDC’s
routine HIV testing recommendations in 2006. It was a much larger sample size than the
study done in Georgia over a longer period (7 years compared to 4). However, unlike our
project, this paper broke up the years into two pooled categories (pre-policy change and
post updated recommendations in 2006) for comparison as opposed to a continuous
trends study as ours will be (2011-2016). The categorical trends analyses did result in
interesting findings showing that there was an increase (albeit temporary) in HIV testing
rates after the new recommendations came out compared to immediately prior the
updates, although they were still lagging behind pre-recommendation highs.
Gaines, 2016 focused on the relationship between the CDC expanded testing
initiative (ETI) funding and past-year HIV testing using the 2012 BRFSS. This study
looked at the odds of being tested for HIV based on if the state they resided in had ETI

46

funding or not. The major caveat in this study was that it focused on testing for HIV
within the past year (based on responses given in the BFRSS). The sample size was the
largest of any of the previously mentioned studies as it was a national study but only
included one year of data collection. Our study will differ from the Gaines, 2016 paper in
that it will look at HIV testing within the past year as well as having ever been tested for
HIV among different subpopulations over a five-year period as opposed to just one year.
As mentioned, the above studies have differing yet important objectives regarding
exploring HIV testing using BRFSS data. A major void remains in the literature
regarding examining HIV testing rates (ever and in past 12 months) overall and among
subpopulations across time. Moreover, we have shaped our 3rd aim objectives to directly
address this gap.
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CHAPTER 3

METHODS
3.1 Overview
To fill in the gaps in the literature and answer these important questions, we used
a variety of datasets such as BRFSS to examine HIV testing rates overall and among
different subpopulations. We also used spatial data obtained from the CDC (via Freedom
of Information Act Request on September 30th, 2017) to examine spatial accessibility to
HIV testing facilities. To determine coverage and supply sufficiency, the total population
of each county will be utilized to calculate a facility density (per 100,000). We will be
classifying rurality at the census tract with the Rural-Urban Commuting Area Codes
(RUCA) obtained from the USDA Economic Research Service (ERS) website. For
counties that either have missing or suppressed HIV prevalent case counts as reported by
Emory University’s AIDSVu website, we will utilize innovative area-level small area
estimation (SAE) techniques to model prevalence rates for all U.S. counties.
These datasets were supplemented by covariate data from sources such as the
Robert Wood Johnson Foundation County Health Rankings which provides county level
demographic data (e.g., race, gender), socioeconomic data (e.g., health care costs,
insurance status, median household income), data on health behaviors (e.g., excessive
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drinking and adult smoking), access to medical care (Primary Care Physician ratio and
Mental Health provider ratio) and other health outcomes (e.g., diabetes incidence rates).
County level age data will come from the U.S. Census Bureau American Community
Survey and education status compiled by the Economic Research Service branch of the
United States Department of Agriculture. Further explanation on the methods and
analysis of the data for each paper is below.
3.2 Paper 1 Methods
3.2.1 Data Sources
We included data from secondary data sources such as the U.S. Department of
Health and Human Services’ HIV.gov, Emory University’s AIDSVu.org, the USDA
Economic Research Service (ERS) and the Health Innovation Program at the University
of Wisconsin-Madison School of Medicine & Public Health.
The latitude and longitude coordinates for HIV rapid and conventional testing
centers were obtained from the CDC through a Freedom of Information Act Request on
September 30th, 2017, along with facility physical addresses and are current as of
September 2017. This database will be used to map facilities across the South for the
purpose of measuring spatial accessibility to HIV resources. We will utilize U.S. census
block group boundaries, obtained from the U.S. Census Bureau, in determining facility
coverage of the affected population. Rurality at the census tract level will be classified as
either: Metropolitan, Micropolitan, Small Town, or Rural through use of the Rural-Urban
Commuting Area Codes (RUCA) obtained from the ERS. Populations affected by HIV
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(i.e., prevalence data) in 2014 will be obtained at the county level from Emory
University’s AIDSVu.org website.
Area deprivation data, specifically the area deprivation index (ADI), was obtained
from the HIP at the University of Wisconsin-Madison. The ADI® is used “as a proxy
measure for socioeconomic status to capture patient-level social risk factors not currently
available in clinical information systems”. The ADI score takes into account 17 different
markers of socioeconomic status such as income disparity, percent of families below
poverty level, education level among others. The full list of variables used to formulate
the ADI score will be provided in Appendix A. The collected data is then standardized
and analyzed via factor analysis to condense variables into categorized components. The
direction of the components (positive or negative) are then validated and combined to
determine that area’s index score. The median score for the ADI is 100 and the higher the
score, the more deprived the area is deemed to be. More information on the index can be
found on the Health Innovation Program’s website. It is believed that the more deprived
an area is, the more susceptible it is to health disparities and poor health outcomes.
3.2.2 Data Analysis
Basic choropleth maps were used to display the county level ADI scores and HIV
testing facility density data. After geocoding and mapping the facility locations, we
conducted accessibility analyses via road distance measures at the census tract level. We
created a 30-minute drive time buffer around each HIV testing facility and assessed the
proportion of population-weighted census tract centroids that fell outside of each of the
“coverage zones”. The characteristics of the populations in the census tracts that fell in
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vs. out of the coverage zones were subsequently examined to identify differences
between areas we classified as having reasonable access to one or more HIV testing
facilities and those who have a farther, less convenient drive to a testing facility.
We then calculated a new variable for facility density, adjusting by total
population, at the county level and displayed those values via a choropleth quintile map.
This takes into account supply of HIV testing compared to a potential demand, as
opposed to a raw density map which does not take into account the population size of the
area. We created a bivariate map of the facility count per 100,000 overlaid with area
deprivation scores to examine the relationship between supply of testing and available
economic resources.
Lastly, to assess the significance of the differences between populations who live
in census tracts within 30 minutes of a HIV testing facility and those who live in CTs
outside of the coverage zone, we conducted a multivariate regression analysis to assess
relationships. We first ran univariate regression analyses followed by a backwards model
selection (cutoff: p<0.2) to determine which variables to include in the final multivariate
logistic regression model. Odds ratios and 95% confidence intervals were obtained from
the regression analyses to assess the odds of being located within 30 minutes of a HIV
testing facility, given the demographic characteristics of the area.
3.3 Paper 2 Methods
3.3.1 Data
The primary data source of HIV prevalence rates in this study is the AIDSVu
2014 HIV prevalence data set. The data comes from the CDC national HIV surveillance
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database and encompasses all U.S. states, counties in 48 of the states, and ZIP Codes in
41 major cities.
All HIV diagnoses reported in the dataset are based on an established case
definition by the CDC. Medical providers, laboratories, and other organizations providing
HIV testing services report HIV cases to the state or local health department, who then
report it (deidentified) to the CDC for national monitoring.
To obtain estimates of HIV prevalence in counties that either having missing or
masked rates, the AIDSVu dataset is used in conjunction with county and state level
covariate data obtained from the following secondary data sources: The Robert Wood
Johnson Foundation County Health Ranking System, the U.S. Census American
Community Survey, and the U.S. Department of Agriculture.
3.3.2 Small Area Estimation Methodology
The purpose of small area estimation (SAE) is to estimate parameters
corresponding with small geographic areas or subpopulations by utilizing the data
available from surrounding areas (Dey). Our model will be borrowing strength from
available HIV rates in neighboring counties and covariate data to estimates the missing
HIV rates. The overall modeling procedure that will be used to run the small area
estimation technique will be a Poisson model with standard Proc GLIMMIX procedure.
This model is good to use if we anticipate some counties to have very small HIV
rates/counts which we do particularly in the Midwest region of the country where the
general population is sparse and spread out. In terms of the variable selection process, we
will be conducting a backwards model selection where we will be more inclusive than
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exclusive in selection taking into account statistical and practical (literature review)
evidence so we will be using a conservative cutoff of p< 0.1 for covariate inclusion in the
final model. Poisson regression models such as the one that will be used are better suited
for using area-specific auxiliary data as opposed to unit-specific data 91 which is
appropriate for our study as all the auxiliary data is at the area level.
The following covariates were tested for model selection, all at the county level
unless otherwise noted: median age, race (%African American, %Asian, %Hispanic,
%White), gender (% female), insurance status (%Uninsured), median household income
(in dollars), education level (% with bachelor’s degree and % with high school degree) ,
excessive alcohol consumption (% of adults reporting binge or heavy drinking),
chlamydia incidence rate, syphilis incidence rate, poverty level (% poverty), primary care
physician to population ratio (PCP ratio), policy regarding HIV education (discussing
condom use in schools or not-yes/no) regionality (breakdown discussed below) and state.
After conducting the small area estimation, we calculated the prevalence rate (per
100,000) of HIV in each county and assessed the validity of the model (validation
techniques mentioned below).
3.3.3 Formulas and Notation
The preliminary general modeling formula used as the structure to set up the SAE is as
follows:
log(𝜆𝑖𝑗 ) = log(𝑛𝑖𝑗 ) + 𝑋𝑖𝑗 𝛽 + 𝑏𝑗
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where for county i in state j, 𝑛𝑖𝑗 is the population, 𝑋𝑖𝑗 are the covariate data, 𝛽 are the
regression coefficients and 𝑏𝑗 ~𝑁(0, 𝜎𝑏2 ) is a random effect. The above model uses
covariates and a random effect at the state level. It is to be noted that the assumption for
this SAE is 𝑌𝑖𝑗 ~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆𝑖𝑗 ) were 𝜆𝑖𝑗 = expected (predicted) number of counts (HIV
prevalent case counts).
3.3.4 Spatial Modeling Component
HIV in the U.S. has distinct characteristics based on geographic location as
different subgroups are more or less affected regionally by HIV; therefore, spatial
modeling will be included using regional indicators at state level (South, Northeast,
Midwest and West). More granular types of spatial modeling, such as the ICAR approach
on the county level, would be difficult due to so the predominance of missing county
level data in very rural states (e.g., Montana and the Dakotas). In this case, counties may
have no neighboring counties with data and a county level ICAR model would not help
with predictions of HIV rates.
3.3.5 Validation Analysis
As small area estimation is in fact an estimation analysis, the results will need to
be assessed and validated. There are various validation techniques that would be suitable
and used for this dataset. There are a few techniques which use already available rates to
validate the estimated values such as the 10-fold cross validation technique (Kohavi),
where we would assign each county randomly a number from 1-10 with 10% of the
counties per partition and then we would run 10 models where you take a different
partition out of the model (called the validation or testing set), and run the model with the
remaining partitions (called the training set). We will be able to properly validate and
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estimate the out-of-sample error for each county in the dataset between observed and
predicted rates. Another strategy would be to remove a small subset of counties with
already available HIV rates, run the SAE model and compare the percent agreement
between the estimated HIV prevalence rates and the direct rates.
A few other cross-validation techniques will utilize statistical mapping such as a
calibration curve or the receiver operating characteristic (ROC) curve, which is used to
evaluate and compare the performance of a diagnostic test and is useful for assessing the
accuracy of predictions (Gonen). We would use the ROC curve to compare the direct
estimate (y-axis on the curve) and model-based estimate (x-axis on the curve). In other
words, a ROC curve is focused on the sensitivity and (1-minus) the specificity. We can
also assess the proportion of HIV found in the county that is observed and predicted by
the SAE model and find the difference in proportions. Validating the data predicted will
be key in the credibility of this project so we will be utilizing more than one of the
validation techniques listed above.
3.4 Paper 3 Methods
3.4.1 Study Design
This was a cross-sectional study done by analyzing self-reported HIV testing data
from the 2011-2017 Behavioral Risk Factor Surveillance System (BRFSS) which is a
nationally representative survey. It is the largest continually conducted health survey in
the world and collects data from over 400,000 adults annually.
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3.4.2 Sample and Data Source
BRFSS is a nationally representative phone-based survey for all 50 states and the
District of Columbia and comprehensively explores health behaviors, chronic health
conditions and healthcare use. Since 2011, the sampling methodology for the BRFSS has
been altered, including an update to its data weighting methodology and incorporating
cellular phone-based surveying. From 2011-2017, the BRFSS has surveyed over 3
million adults across the nation. Of those, our study included all who answered the
question “Have you ever been tested for HIV, excluding tests as part of a blood
donation?” and excluded those who refused or did not answer the HIV-related questions.
3.4.3 Measures
The main dependent variable looked at was overall self-reported HIV testing
percentages which was assessed via the set of questions asked in the 2011-2017 BRFSS
about if the participant had ever been tested for HIV, excluding tests as part of a blood
donation. If the participant answered ‘yes’, further questioning assessed the date and
location of the last HIV test. Secondarily, we are interested in assessing past-year HIV
testing percentages. We will create a binary variable (yes vs no) identifying if they had
been tested within 12 months prior to the interview to assess this objective based on date
of last reported HIV test.
The independent variables include demographic data and health behavior
indicators which were collected at the individual level. Data on variables associated with
HIV testing were collected across the targeted 7-year range of surveys and included: age
in years (18–24, 25–34, 35–44, 45–54, 55–64, or 65+), sex (male or female),
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race/ethnicity (non-Hispanic (NH) white, NH black, NH Asian, NH Native
American/Alaskan, NH Native Hawaiian/Pacific Islander or Hispanic), educational
attainment (<high school, high school graduate, some college and college graduate),
current employment status (employed, self-employed, out of work <1 year, out of work>
1 year, homemaker, student, retired or unable to work) annual household income in
United States Dollar (USD (<$25,000, $25,000-$50,000, $50,000-$75,000 and
$75,000+)), marital status (married, divorced, widowed, separated, or never married,);
healthcare coverage (yes/no).
Risky health behavior measures were also included such as being classified as a
binge drinker (yes/no), current smoking status (everyday, some days or not at all) and
engaging in any of the following HIV risk behaviors in the past year (HIV high-risk
situations (yes/no)) - use of intravenous drugs, treatment for sexually transmitted disease,
giving or receiving money or drugs for sex, or having anal sex without a condom.
3.4.4 Analysis
We obtained the weighted percentages of respondents who had ever been tested
for HIV stratified by the socio-demographic and health behavior indicators listed above.
Additionally, we will calculate the average weighted percentage and average annual
percent change over the 7-year period to assess reporting trends during that time. We will
run regression analyses to assess the association between ever being tested for HIV and
the socio-demographic variables listed above, using data pooled from 2011-2017. We
will run a second regression model to assess the association between being tested for HIV
within the past 12 months and socio-demographic variables. The estimates in both
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regression models will be adjusted for by the demographic variables and selected health
behavior indicators (age, gender, race/ethnicity, educational attainment, current
employment status, annual household income, healthcare insurance coverage, marital
status, binge drinker status and smoking status). To account for differences in data
collection (nonresponse, respondent selection, and telephone non-coverage), the data was
weighted using built-in calculated weights from the BRFSS dataset. Odds ratios, 95%
confidence intervals and p-values will be obtained from the regression analyses.
Regression analyses were run using survey logistic modeling as opposed to standard
logistic regression due to the complex sampling design of the survey (Berglund). All
analyses were performed using SAS version 9.4 software.
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CHAPTER 4

SPATIAL ACCESS TO HIV TESTING ACROSS THE U.S. SOUTH1

1

Khan S, Olatosi B. Torres M, McLain A, Eberth J. Submitted to Aids and Behavior, 11/1/18
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4.1 Abstract
Disparities in access to HIV testing facilities affects early diagnosis, linkage into,
and retention in HIV care across the U.S. South. We obtained the geocoded addresses of
HIV testing facilities across the U.S. South, provided by the CDC, to examine the
associations between access to HIV testing facilities, rurality and socioeconomic area
deprivation in the U.S. South. Results showed rural areas were more likely to be outside
of a 30-minute drive time of a HIV testing facility, particularly in more
socioeconomically deprived areas. Populations in areas outside of the coverage zone, had
a lower average median household income, higher poverty rates and higher rates of being
uninsured compared to populations within the coverage zone. These results can be of
value to public health professionals and policy makers identify areas across the region
that require further attention planning HIV interventions and policies targeting barriers to
HIV care.

Keywords: HIV testing; HIV; Access to Care; Rurality; Geographic Information Systems
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4.2. Introduction
Since the 1980’s, a major focus has been placed on combating the spread of the
Human Immunodeficiency Virus (HIV) in the United States. While progress has been
made, especially in reducing HIV transmission rates [89% decline since mid-1980’s
(“HIV Prevention”)], HIV remains a major problem. The South continues to experience
disproportionately high HIV incidence, reporting over half of all new HIV diagnoses
nationally in 2015 (“HIV in the United States”). Federal efforts to reduce the HIV burden
have included investment in HIV testing, prevention and treatment, including reducing
HIV risk factors like intravenous drug use (IDU) and unprotected sex in men who have
sex with men (MSM) (“HIV Prevention”). These initiatives have resulted in the reduction
of new infections over the past 30-years from 130,000 annually in the mid-1980s to
50,000 in 2010 (“HIV Prevention”).
From 2005 to 2014 alone, there has been an 18% decline in new HIV infections,
primarily in urban areas (“Pellowski”). However, rates of HIV incidence and prevalence
have either remained stable or increased in rural areas, with recently recorded infection
rates at 6% (“HIV in the United States”). Additionally, HIV incidence in the rural south
is higher than in any other rural areas (Pellowski; “HIV in the Southern United States”).
The higher rates are due in part to factors such as lack of access to HIV services,
transportation issues and social stigma (Pellowski 6). Transportation in particular has
been noted as a major barrier to HIV care as it is linked to higher levels of socioeconomic
deprivation (lower levels of income, higher rates of unemployment and higher
dependence on public transit) (Pellowski 4). These issues are magnified in rural areas due
to fewer options for public transportation (or worse efficiency), fewer medical specialists,
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and tight-knit communities leading to a higher likelihood of people finding out if
someone has HIV (Donley). Previous studies found late diagnosis and delayed linkage to
HIV care as also associated with rurality (Oppong; Trepka). HIV incidence and
prevalence also affect races differently as minority populations are disproportionately
affected by HIV. Black Americans accounted for 54% of all new HIV diagnoses and
black women accounted for 69% of all new diagnoses among women in the south in 2014
(“HIV in the Southern United States”). The HIV outbreak in rural Indiana from 2015
highlights the dangerous intersection of HIV risk indicators in rural areas such as a HIVrelated risky health behavior (intravenous drug use), poverty and a lack of proper HIVrelated resources in the area (Ungar).
A major gap exists in the literature regarding spatial accessibility and proximity to
HIV testing and treatment facilities, as relevant studies have been conducted mostly in
urban settings (Dasgupta et al.; Ganapati) or abroad (Fulcher). While studies focused on
metropolitan areas do provide valuable information and groundwork for future studies,
there are still major gaps in understanding the rural population living with HIV
particularly in the understudied rural south. Access to HIV testing-related resources is
important for controlling the HIV epidemic and reducing time to diagnosis and treatment
(Pellowski). However, few studies have identified specific areas with poor spatial
accessibility to HIV testing facilities, particularly in rural communities, or detailed the
environmental context of such areas (Dasgupta et al.; Ganapati). A recent publication by
Kimmel et.al, assessed spatial accessibility across the south at the county level which has
provided an important foundation for research on this topic. However, as levels of

62

rurality can vary across a county, a more granular examination of local-area resources
(e.g., census tract level) is warranted.
The purpose of this study is to examine spatial accessibility to HIV testing
facilities across the southern U.S., along with measures of area socioeconomic
deprivation and other HIV risk indicators. As rurality increases, we hypothesize that
residents will experience suboptimal access to HIV testing-related resources, particularly
in more socioeconomic deprived areas. We also hypothesize that areas with higher
proportions of minorities, regardless of rurality, will exhibit lower levels of spatial
accessibility to HIV testing facilities.
4.3 Methods
4.3.1 Data Sources
We included data from secondary data sources such as the U.S. Department of
Health and Human Services’ HIV.gov, Emory University’s AIDSVu.org website, the
USDA Economic Research Service (ERS), the U.S. Census Bureau and the Health
Innovation Program (HIP) at the University of Wisconsin-Madison School of Medicine
& Public Health (UW).
The HIV rapid and conventional testing centers were geocoded through data
obtained from the Centers for Disease Control and Prevention (CDC) through a Freedom
of Information Act (FOIA) request and are accurate as of September 2017. The geocoded
facilities were mapped using ArcGIS Version 10.2.2 across the South to measure spatial
accessibility to HIV testing resources. We utilized U.S. census tract (CT) boundaries,
obtained from the U.S. Census, in determining facility coverage of the affected
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population. Rurality at the census tract level was classified as either: Metropolitan,
Micropolitan, Small Town, or Rural through use of the Rural-Urban Commuting Area
Codes (RUCA) obtained from the ERS. Each category is defined based on “measures of
population density, urbanization, and daily commuting” (“Rural-Urban Commuting Area
Codes”). Data used for the codes were extracted from the 2010 Decennial Census and the
2006-2010 American Community Survey. Separately, population estimates provided by
the U.S. Census Bureau was coupled with the count of HIV testing facilities obtained
from the CDC to create a county-level facility density variable (per 100,000).
The 2016 American Community Survey from the U.S. Census was then used to
gather demographic data: race (Non-Hispanic American Indian, Non-Hispanic Asian,
Non-Hispanic Black, Non-Hispanic Hawaiian/Pacific Islander, Non-Hispanic White),
ethnicity (Hispanic or Non-Hispanic), educational attainment (% with bachelor’s degree
by race/ethnicity), insurance status (% Uninsured overall, %uninsured under 18 years old,
%uninsured 18-64 year olds, %uninsured 65+, %uninsured among females %uninsured
among males) , median household income ($), poverty rates (%overall, %under 18 years
old, % 18-64 year olds, % 65+, % among females % among males) at the census tract
level for areas with and without access to one of the geocoded HIV testing facilities (see
Data Analysis section for details on measuring access).
Area deprivation data, specifically the Area Deprivation Index (ADI®), was
obtained from the HIP at the University of Wisconsin-Madison. The ADI® is used “as a
proxy measure for socioeconomic status to capture patient-level social risk factors not
currently available in clinical information systems” (Singh). The ADI® score takes into
account 17 different markers of socioeconomic status such as income disparity, percent
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of families below poverty level, education level among others. The collected data is then
standardized and analyzed via factor analysis to condense variables into categorized
components. The direction of the components (positive or negative) are then validated
and combined to determine that area’s score (Knighton et al.). The score for the ADI®
comes in two forms, one assessing the deprivation of an area relative to the rest of its
state (score 0-10) and one assessing the deprivation relative to the entire country
(percentile score out of 100). The higher the score or percentile, the more deprived the
area is deemed to be (Pampel et al.). More information on the index can be found on the
Health Innovation Program’s website.
4.3.2 Data Analysis
Basic choropleth maps were used to display the county level ADI scores and HIV
testing facility density data. After geocoding and mapping the facility locations, we
conducted accessibility analyses via road distance measures at the census tract level. We
created a 30-minute drive time buffer around each HIV testing facility and assessed the
proportion of population-weighted census tract centroids that fell outside of each of the
“coverage zones”. A 30-minute travel time to care is considered an accessibility threshold
for travel for primary care (Kimmel and Masain). The characteristics of the populations
in the census tracts that fell in vs. out of the coverage zones were subsequently examined
to identify differences between areas we classified as having reasonable access to one or
more HIV testing facilities and those who have a farther, less convenient drive to a HIV
testing facility (farther than 30-minutes).
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We then calculated a new variable for facility density, adjusting by total
population, at the county level and displayed those values via a choropleth quintile map.
This takes into account supply of HIV testing compared to a potential demand, as
opposed to a raw density map which does not take into account the population size of the
area. We created a bivariate map of the facility count per 100,000 overlaid with area
deprivation scores to examine the relationship between supply of testing and available
economic resources in the area.
Lastly, to assess the significance of the differences between populations who live
in census tracts within 30 minutes of a HIV testing facility and those who live in CTs
outside of the coverage zone, we conducted a multivariate regression analysis to assess
relationships. We first ran univariate regression analyses followed by a backwards model
selection (cutoff: p<0.2) to determine which variables to include in the final multivariate
logistic regression model. Odds ratios and 95% confidence intervals were obtained from
the regression analyses to assess the odds of being located within 30 minutes of a HIV
testing facility, given the demographic characteristics of the area.
4.4 Results
The main objective of our study was to examine spatial accessibility to HIV
Testing Facilities across the U.S. South and identify areas where there are greater
disparities. Table 4.1 displays the average proportion of census tracts that fall out of the
pre-defined 30-minute drive time coverage zone from a HIV testing facility, categorized
by RUCA location type. 14.70% of census tracts classified as “rural” in the U.S. south
were identified as falling out of the 30-minute coverage zone while 1.34% of census
tracts classified as “metropolitan” were out of range.
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Table 4.2 further shows facility coverage in the U.S. South within each of the 16
states and the District of Columbia. Among the southern states, Texas had the largest
proportion of micropolitan (9.39%), small town (17.75%) and rural (42.54%) census
tracts that fall outside of the 30-minute drive time coverage zone. Alabama had the
second largest percentage of its census tracts classified as rural to be outside of a 30minute drive time of any HIV testing facility (25.34%) while Louisiana had the second
most among small town classified census tracts (14.1%). West Virginia had the greatest
proportion of metropolitan (4.88%) census tracts that fell out of the 30-minute drive time
of any of the geocoded HIV facilities followed by Louisiana (3.25%). Washington D.C.
and Delaware did not have any census tracts that were not covered by a HIV testing
facility within a 30-minute drive-time.
In terms of populations that fell out of the coverage zone, Florida had the largest
proportion of its rural population (34.19%) to be farther than 30-minutes from any of the
geocoded facilities followed by Texas (19.73%) and Alabama (19.14%). Texas had the
largest proportion of its micropolitan (10.43%) and small town (20.70%) populations
along with the populations in West Virginia metropolitan census tracts (4.92%) to be
outside of a 30-minute drive time from any of the facilities.
Table 4.3 displays descriptive statistics comparing the census tract populations
within the 30-minute coverage zone of HIV testing facilities and populations outside of
the coverage zone. Univariate logistic regression yielded significant differences for the
unstratified covariates (P<0.05) between coverage zone inclusion and exclusion). The
census tracts with access to a geocoded HIV testing facility within 30 minutes had a
higher percentage of Asians (2.9%), Black (20.1%) and mixed raced populations (2.6%).
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These populations also had higher median household incomes ($71,265 compared to
$63,398), lower average overall rates of uninsured (14.8% compared to 18.7%), slightly
higher rates of unemployment (8.0%), higher rates of educational attainment for all racial
categories and slightly lower overall poverty rates (17.6%). Standard errors (SE) for each
of the characteristics from table III can be found in appendix B.
Table 4.1 Average Percentage of Census Tracts and
Population outside of HIV Testing Coverage Zone
Location
Metropolitan
Micropolitan
Small Town
Rural

Average % of
CTS
1.34
2.78
4.75
14.17

Average % of
Population
1.24
2.29
4.13
10.66

Table 4.2 Percentage of Census Tracts (and Population) Outside 30-Minute
Drive Time of a HIV testing Facility
Location
AL
AR
DC
DE
FL
GA
KY
LA
MD
MS
NC
OK
SC
TN
TX
VA
WV

Metropolitan
3.07 (2.07)
2.53 (2.82)
0 (0)
0 (0)
0.74 (0.61)
0.38 (0.23)
0.51 (0.58)
3.25 (3.46)
0.37 (0.32)
0.68 (1.21)
1.16 (0.48)
0.77 (0.49)
2.16 (1.25)
1.19 (1.47)
0.84 (0.93)
0.25 (0.25)
4.88 (4.92)

Micropolitan
6.9 (6.58)
5.6 (5.37)
0 (0)
0 (0)
1.23 (0.66)
0.46 (0.24)
1.08 (0.31)
6 (5.14)
0 (0)
0.89 (0.67)
3.39 (2.00)
1.42 (1.76)
4.58 (2.04)
3.51 (1.46)
9.39 (10.43)
0 (0)
2.9 (2.25)
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Small Town
7.78 (6.73)
8.41 (9.05)
0 (0)
0 (0)
2.13 (2.14)
2.33 (1.38)
3.65 (2.25)
14.1 (10.47)
0 (0)
2.04 (1.86)
1.96 (0.46)
3.03 (1.02)
2.44 (0.92)
4.2 (5.44)
17.75 (20.70)
7.29 (4.86)
3.7 (2.96)

Rural
25.37 (19.14)
20.69 (17.91)
0 (0)
0 (0)
25.24 (34.19)
1.37 (0.80)
9.35 (7.97)
10.64 (15.09)
7.14 (9.17)
2.08 (3.86)
24.76 (16.67)
20.69 (12.35)
9.68 (3.74)
13.79 (2.44)
42.54 (19.73)
6.38 (4.12)
21.21 (13.97)

Table 4.3 Average Demographics of Residents in Census Tracts in or Outside of 30
Minutes of HIV Testing Facilities

Variable

No Access (N=598)

Access
(N=24,063)

0.8
0.8
6.7
0.1
86.2

0.7
2.9
20.1
0.1
70.7

19.2
80.8

16.2
83.8

18.4
20.8
39.0
10.3
10.8
18.8
21.4
63,398.24
6.9

27.6
20.8
48.0
22.5
21.5
23.4
31.4
71,265.65
8.0

18.7
12.3
27.2
0.6
17.7
19.2

14.8
7.3
21
1.3
13.6
16.0

1.3
2.8
4.8
14.2

98.7
97.2
95.3
85.8

18.0
25.8
17.1
11.2
19.4
16.1

17.6
24.0
16.4
11.3
18.9
16.1

Race (%; p<0.0001)
American Indian
Asian
Black
Hawaiian/Pacific Islander
Non-Hispanic White
Ethnicity (%; p<0.0001)
Hispanic
Not Hispanic
Education (% with bachelor’s degree;
p<0.0001)
Overall
American Indian
Asian
Black
Hispanic/Latino
Hawaiian/Pacific Islander
Non-Hispanic White
Income (average $; p<0.0001)
Unemployment Rate (%, ages 16+; p<0.0001)
Uninsured (%; p<0.0001)
Overall
Under 18
18-64
65+
Female
Male
Rurality (%; p<0.0001)
Metropolitan
Micropolitan
Small Town
Rural
Poverty Rate (%; p<0.0001)
Overall
Under 18
18-64
65+
Female
Male
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Census tracts located outside of a HIV testing facility coverage zone had an
average higher percentage of non-Hispanic whites (86.7%), higher rates of uninsured
among the 18-64 age category (27.2%) and both genders (17.7% for females and 19.2%
for males), higher poverty rates among the under 18 (25.8%) and 18-64 (17.1%) age
categories and both genders (19.4% for females and 16.1% for males).
Tables 4.4 and 4.5 display the results of a univariate and multivariable logistic
regression to examine associations between access to an HIV testing facility (within 30minute drive time) and selected sociodemographic covariates. All characteristics except
percent female (p=0.37) and percent Hispanic (p=0.5671) were significantly associated
with access to HIV testing. Controlling for the other covariates in the model % uninsured
was significantly associated with being in a HIV testing facility zone (OR=0.93; 95%CI=
0.91, 0.95; p<0.0001).
Table 4.4 Univariate Regression: Odds of Being Located in a HIV Testing Facility
Coverage Zone Across Census Tract Sociodemographic Characteristics

Variable

Crude OR

% Black
% Hispanic
% White
% Female
% with bachelor’s Degree
% Uninsured
% below poverty
Rural (Vs Urban)
Unemployment Rate

0.989
1.001
1.010
0.997
1.019
0.974
0.961
0.47
0.944
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95% CI
0.988
0.999
1.009
0.989
1.017
0.970
0.959
0.401
0.938

0.990
1.002
1.011
1.004
1.022
0.978
0.964
0.552
0.950

PValue
<0.0001
0.5671
<0.0001
0.3771
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

Table 4.5 Multivariate Logistic Regression: Odds of Being Located in a HIV Testing
Facility Coverage Zone Across Census Tract Sociodemographic Characteristics

Variable

Adjusted OR

% Black
% Hispanic
% White
% Female
% with bachelor’s Degree
% Uninsured
% below poverty
Rural (Vs Urban)
Unemployment Rate

1.04
1.00
1.00
1.03
1.01
0.93
1.03
0.06
1.05

95% CI
1.01
0.99
0.97
1.00
1.00
0.91
1.01
0.04
1.01

1.07
1.01
1.02
1.06
1.03
0.95
1.05
0.09
1.09

PValue
0.006
0.785
0.717
0.021
0.070
<.0001
0.012
<.0001
0.009

Also, adjusting for the other covariates in the model, living in a rural setting was
significantly associated with lower odds of being in a HIV testing facility coverage zone
compared to urban settings (OR=0.06; 95%CI= 0.04, 0.09; p<0.0001) in the South. The
magnitude for the association between rurality and access to HIV testing was further
strengthened when included in the multivariate model compared to the univariate analysis
between rurality and access.
Table 4.6 Multivariate Logistic Regression: Odds of Being Located in a HIV Testing
Facility Coverage Zone Across Stratified Census Tract Sociodemographic Characteristics
Variable
% below Poverty
% below Poverty
(Males)
% Uninsured ages
18-64
% Asian with
bachelor’s degree
% Black with
bachelor’s degree
% White alone with
bachelor’s degree

Adjusted Odds Ratio
1.623
0.541

95% CIs
0.965,2.728
0.315,0.930

P-value
0.0676
0.0261

0.836

0.702,0.995

0.0438

1.114

1.018,1.220

0.0192

1.209

1.011,1.444

0.0370

0.472

0.209,1.070

0.1260
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% native
Hawaiian/P.C. with
bachelor’s degree
% White

0.968

0.938,0.999

0.0457

0.828

0.709,0.967

0.0169

To further examine the associations between access to an HIV testing facility
(within 30-minute drive time) and selected sociodemographic covariates, we stratified
each of the covariates conducted model selection (“a priori” literature information and
univariate regression with cutoff: p<0.2) and ran multivariate logistic regression. The
final model, results displayed in table 5, was paired down to 8 covariates, 6 of which had
a statistically significant effect (p<0.05) in the model. Two of the six remaining
covariates in the final model dealt with poverty rates and four dealt with educational
attainment (bachelor’s degree) stratified race/ethnicity.
Percentage of adults aged 18-64 uninsured was found to be negatively associated
with one’s odds of being in a HIV testing facility coverage zone. Controlling for the other
covariates in the final model, % uninsured among the 18-64 age category was
significantly associated with lower odds of being in an HIV testing facility coverage zone
decreased. Controlling for other covariates, % male below poverty was also significantly
negatively associated with lower odds of being in a HIV testing facility coverage zone
(OR=0.54; 95%CI= 0.32, 0.93; p<0.026), as was % white (OR=0.83; 95%CI= 0.71, 0.97;
p<0.0169). % white being significantly associated in table 5 is in contrast to the result of
table IV where % white was not significantly associated with being located within a HIV
testing facility coverage zone.
On the opposite spectrum, the largest positive association with access to a HIV
testing facility, was among percent of blacks with a bachelor’s degree or higher.
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Controlling for other covariates, % blacks with a bachelor’s degree was associated with
higher odds of the census tract being located within a HIV testing facility coverage zone
(OR=1.21; 95%CI= 1.01, 1.44; p<0.037). Percentage of Asians with a bachelor’s degree
or higher was also positively associated with a census tract’s odds of being located within
a HIV testing facility coverage zone (OR=1.11; 95%CI= 1.02, 1.22; p-value=0.019).
Figure 4.1 displays the average area deprivation index (ADI) score, aggregated
and categorized in qunitiles (quintile 1 is least deprived and quintle 5 is most) at the
county level across the U.S. South. The map shows consistently high levels of econocmic
deprivation in rural parts of most states particularly in the deep south states such as
Texas, Arkansas, Mississippi, Alabama and Kentucky. Texas in particular shows the
stark contrast in terms of socioeconomic resources between metropolitan and rural
communities as the counties considered to be in the lease deprived quintiles (1 and 2) are
some of the more populous counties in the state (Austin, Dallas, and San Antonio) while
the areas considered more economically deprived (quintile 4 and 5) were in the more
rural northwestern portion of the state.
The more northern located of the southern states (Virginia and Maryland) had a
noticable higher proportion of its counties be considered less socioeconomically deprived
(quintle 1 and 2) compared to the rest of the south, as shown in figure 1.
Figure 4.2 displays the supply of HIV testing facilities (facility count per 100,000
population) at the county level across the U.S. South. Similar to figure 4.1, the lower
densities of HIV testing facilities were located in the more rural areas (identified in dark
and light green) while the more dense supply of HIV testing facilities were located in
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more urban settings though at a lesser extent than shown in figure I, after taking
population size into account. Arkansas, which had a large proportion of its rural
communities outside of 30-minute drive time of any HIV testing facilities (table 4.2),

Figure 4.1 County Level Area Deprivation Index (ADI) across the U.S. South

Figure 4.2 HIV Testing Facility Density (per 100,000) by County across the U.S
South
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Figure 4.3. BiVariate Map of ADI with Facility Density (per 100,000)

when taking populaiton size into account is shown in table 3 as having adequate supply
of facilities across most of the state. Figure 4.3 displays the overlay of the ADI and
facility density at the county level across the U.S. South. In particular, the northwestern
and notiblely more rural, region of Texas is shown to have a combination of high
socioeconomic deprivation and lower concentrations of HIV testing facilities with a
number of counties identified to have the most disadvantaged intersection (quintles 4 and
5 for both category; noted in dark red). On the opposite spectrum, there are a couple of
counties that have both a high density of testing facilities and less socioeconomically
disadvantaged population (Monroe County, FL for example).
Many of the counties across the U.S. South as shown in Figure III, had similar
levels of area deprivation and supply of HIV testing facilities. Florida in particular,
showed a lot of parallels between a county’s level of economic deprivation and its supply
of HIV testing facilities.
Arkansas, on the other hand, had a largely inverse association between area
deprivation and supply of HIV testing facilities, as large region of counties in the
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southern part of the state were highlighted in blue, signifiying a high density of testing
facilities in areas perceived as highly economically deprived.
4.5 Discussion
This study, examining access to HIV testing facilities across the U.S. South
(provided by the CDC), shows that there is a disproportionate lack of access to HIV
testing in rural areas, when compared to other area classifications. Previous literature
(J.A. Pellowski; Giordano et al.; Reif et al.), has shown that transportation, lack of access
to HIV services and lack of insurance are all major barriers in combatting the HIV
epidemic, all of which are of even greater concern in rural areas due to scarcity of all of
the mentioned resources and increased distance to services.
Another by-product of these barrier is that rurality was associated with lower odds
of reporting being ever tested for HIV and being tested within the past year (Henderson et
al.; Ohl and Perencevich). The lack of access to HIV testing in rural settings in the south
is even more revealing when focusing on states individually, particularly in the “deep
south”. Rural areas in the Deep South states of Texas, Florida and Alabama had the
highest percentage of census tracts that fell outside of a 30-minute drive time of an HIV
testing facility of any kind. The other three area classifications were relatively well
covered as no one classification in any of the states had over 14.1% (Louisiana) of its
census tracts farther than a half-hour drive to a HIV testing facility, which is the average
proportion of census tracts in rural areas that were without coverage.
The average demographics of the census tracts within and outside of the coverage
zone indicated disparities between the two groups. The average median income for
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census tracts outside of 30 minutes of a HIV testing facility was lower ($63,399) than that
of a census tract within the range ($71,266). The percentage of uninsured among all age
groups (aside from 65+) and genders, regardless of rurality were higher among census
tracts outside of the coverage zone. The same is true of poverty rates among all age
groups and genders being higher in the census tracts outside of the zone. When looking at
the multivariate logistic regression model (table 5), it indicated that being a male below
the poverty level and being uninsured between the ages of 18-64, was significantly
associated with having lower likelihoods of having access to HIV testing. This provides
further evidence to claims that previous literature (Pellowski; Reif et al.; Ohl and
Perencevich) have made about the disparate lack of access to HIV services due to
socioeconomic factors such as poverty and insurance status, particularly in the U.S.
South. Inversely, there was a significantly positive association between % black with a
bachelor’s degree and access to HIV testing. As the percentage of black with a bachelor’s
degree (regardless of rurality) in the census tract increases, so does the likelihood of that
census tract being within 30 minutes of an HIV testing facility.
Figures 4.1-4.3 further explored the socioeconomic-access to HIV testing
dynamic and again highlighted the relationship that is perceived to be there. Northwest
Texas (predominantly rural) had the most perilous combination of high levels of area
deprivation coupled with low facility density levels. Most of the counties across the U.S.
south fell in the middle of the spectrum for both factors with only a few locations
showing opposite relationships between the two. Parts of Arkansas, Georgia, and
Mississippi had worse levels of area deprivation coupled with higher facility count per
100,000 (though the original population in many of those areas are rather sparse). In
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general, the maps provide further evidence that there is a relationship between access to
HIV testing and socioeconomic factors, which as mentioned, becomes more disparate and
a greater concern as rurality increases.
Our study had several strengths and limitations. Major strengths of our study
included the updated and comprehensive list of HIV testing facilities compiled by the
CDC and the more granular degree to which we conducted our analyses (census tract
level as opposed to county level). Also, the generalizability of the study is strong for rural
areas as the barriers that hinder HIV testing in rural settings, while most problematic in
the south, plagues rural settings across the country as a whole. Limitations include the
use of the general population instead of population at risk for the HIV facility density
calculations though it still provides a good basis for examining HIV testing supply based
on population size. Also, this study solely focuses on access to HIV testing in the south
and not the next steps in HIV care. Further research would involve examining spatial
access to the full continuum of HIV services (prevention, testing, and treatment) as a
whole throughout the region.
4.6 Conclusion
This study assessed the spatial accessibility to HCI testing facilities across the
U.S. South and highlighted the disproportionate level of access to such services as
rurality increased. That, coupled with previous work that showed the lower odds of being
tested for HIV in rural settings (Henderson et al.; Ohl and Perencevich), shows the need
for targeted interventions that will help to remove or reduce structural barriers in rural
communities in the U.S. south, regarding easier access to HIV testing. Our findings can
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help policy makers and public health officials identify areas across the region that require
further attention and potentially, consider alternative methods to provide HIV testing
services to those areas (such as mobile clinics).
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CHAPTER 5

SMALL AREA ESTIMATION OF COUNTY-LEVEL U.S. HIV
PREVALENT CASES2

2

Khan S, McLain A, Olatosi B. Torres M, Eberth J. to be submitted to the Annals of
Epidemiology
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5.1 Abstract
Purpose: To estimate HIV prevalence at the county level and to compare prevalence
across the country to assess the burden of HIV in the United States.
Methods: We performed an area-level small area estimation (SAE) modeling technique to
predict the prevalent HIV case count for all counties across the continental U.S. including
unreported counties. Our model borrowed strength from neighboring counties with
reported counts and auxiliary HIV risk-indicator data, including geospatial components.
Cross-validation techniques were conducted to assess the precision of the estimates.
Results: Our findings showed that majority of the unreported counties, mostly in the
Midwest, had low HIV prevalence levels (quintiles 1 and 2). Estimates for unreported
counties in the South remained consistent with the higher levels of HIV burden (quintile
4 and 5) of the rest of the region, indicating location as a strong indicator of HIV burden.
Conclusions: HIV is most prevalent along the coastlines and across the U.S. south. The
cross-validation techniques largely supported the ability of our SAE model to accurately
estimate prevalent case counts at the county level. Our study provides a more complete
picture of the burden of HIV across the U.S. and identifies communities in need of
targeted intervention in the future.

Key words: HIV; HIV prevalence; Small area estimation; county-level estimates
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5.2 Introduction
Human Immunodeficiency Virus (HIV) surveillance statistics are reported and
updated frequently by governing bodies such as the Centers for Disease Control and
prevention (CDC) since the disease was cast into the public spotlight in the 1980s.
Accurate data is crucial in evaluating the burden of disease and assessing areas of need to
better combat the HIV epidemic moving forward. However, there are numerous counties
across the United States where the burden of HIV is unable to be properly assessed due to
publicly available data being either missing, out of date, inexact or suppressed due to low
HIV counts among other reasons. Regardless of the rationale, incomplete publicly
available data can mask areas with potentially rising HIV rates, particularly rural settings
with small populations (“HIV/AIDS in Rural America”). Past research has shown that the
number of HIV cases proportional to the population size in rural settings can be just as
great as the burden of HIV in more populated areas (“HIV/AIDS in Rural America” 1).
The lack of clarity regarding the current burden of HIV in certain rural parts of the U.S.,
mostly in the Midwest and the South, is of great concern given that one out of every five
new HIV diagnoses in those two regions, occur in rural areas (“HIV in the United
States”). There is a great need to fill in these data gaps to better understand the national
HIV epidemic and find potential hot-spots based on a combination of HIV rates and HIVrisk indicators such as race/ethnicity, socioeconomic status and risky health behaviors
such as drug and alcohol abuse.
Given the current geospatial trends of the HIV epidemic, it can no longer being
characterized as solely an urban setting issue (Ungar) hence an increased need for more
accurate and available data to better target areas of need for intervention and policy
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change. Statistical methodologies can be used to produce expected rates of an outcome in
areas with missing or masked HIV data. Recently, numerous studies have utilized unitlevel and area-level small area estimation (SAE) modeling techniques (Mukhopadhyay
and McDowell) to estimate real world outcomes ranging from economics (Roger et al.) to
health outcomes such as under/mal-nutrition rates (Sohensen; Haslett and Isidro) and
diabetes incidence rates (Barker et al). There have not yet been any studies done using
SAE modeling techniques to estimate HIV prevalence rates for local areas with missing
or masked data. We will utilize an area-level SAE modeling technique to tackle the issue
of poor or non-existent HIV prevalence reporting, particularly in rural settings.
Hence, the purpose of our study is to estimate HIV prevalence in counties across
the U.S. with missing case counts and rates as of 2014 and assess the burden of disease in
those areas. We hypothesize that the HIV prevalent case counts predicted by our SAE
model will be considered valid and reliable after statistical validation techniques. Our
study will provide a more accurate picture of the burden of HIV across the U.S. and
identify communities in need of targeted intervention in the future.
5.3 Methods
5.3.1 Data
The primary data source of prevalent HIV case counts in the continental U.S. in
this study is the AIDSVu 2014 National County Level HIV prevalence data set. The data
comes from the CDC national HIV surveillance database which encompasses all U.S.
states, all counties in 48 of the states along with ZIP Codes in 41 major cities.
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All HIV diagnoses reported in the dataset are based on an established case
definition by the CDC. Medical providers, laboratories, and other organizations providing
HIV testing services report HIV cases to the state or local health department who then
reports it (deidentified) to the CDC for monitoring of the national HIV condition.
To obtain estimates of HIV prevalence in counties that either having missing or
masked rates, the AIDSVu dataset is used in conjunction with county and state level
covariate data obtained from the following secondary data sources: The Robert Wood
Johnson Foundation County Health Ranking System , the U.S. Census American
Community Survey, and the U.S. Department of Agriculture.
5.3.2 Small Area Estimation Methodology
The purpose of small area estimation (SAE) is to estimate outcomes
corresponding with small geographic areas or subpopulations by utilizing the data
available from surrounding areas (Rogers et al.). Our model borrowed strength from
available HIV rates in neighboring counties and covariate data to estimate the prevalent
HIV case counts. The overall modeling procedure that was used to run the small area
estimation technique was a mixed-effects Poisson regression model estimated with Proc
GLIMMIX in SAS v9.4. This model was chosen for use as it is equally efficient in
estimating very small HIV counts as well as larger HIV counts as we anticipate a
variation in count and population sizes across the country. In terms of the variable
selection process, we conducted a backwards model selection (after initial variable
selection through past literature) with a cutoff of p< 0.2 for covariate inclusion in the
final model. Poisson regression models are suited for using area-specific auxiliary data as
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opposed to unit-specific data (Dey). which was appropriate for our study as all the
auxiliary data is at the area level (county and state-level).
The following covariates were tested for model selection, all at the county level
unless otherwise noted: median age, race (%African American, %Asian, %Hispanic,
%White), gender (% female), insurance status (%Uninsured), median household income
(in dollars), education level (% with bachelor’s degree and % with high school degree) ,
excessive alcohol consumption (% of adults reporting binge or heavy drinking),
chlamydia incidence rate, syphilis incidence rate, poverty level (% poverty), primary care
physician to population ratio (PCP ratio), policy regarding HIV education (discussing
condom use in schools or not-yes/no), regionality (breakdown discussed below) and state.
The resultant parameter estimates from the final model (general model structure
shown below) were used to estimate county HIV prevalent case counts and 95%
confidence intervals (CI). Furthermore, we used a combination of the observed and
predicted prevalent HIV case counts to calculate the HIV prevalence rate (per 100,000) at
the county-level across the country.
5.3.3 Formulas and Notation
The preliminary general modeling formula used as the structure to set up the SAE is as
follows:
log(𝜆𝑖𝑗 ) = log(𝑛𝑖𝑗 ) + 𝑋𝑖𝑗 𝛽 + 𝑏𝑗
where for county i in state j, 𝑛𝑖𝑗 is the population, 𝑋𝑖𝑗 are the covariate data, 𝛽 are the
regression coefficients and 𝑏𝑗 ~𝑁(0, 𝜎𝑏2 ) is a random effect. The above model uses
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covariates and a random effect at the state level. It is to be noted that the assumption for
this SAE is 𝑌𝑖𝑗 ~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆𝑖𝑗 ) were 𝜆𝑖𝑗 = expected (predicted) number of counts (HIV
cases).
5.3.4 Spatial Modeling Component
HIV in the united states while an issue across the country, has distinct characteristics
based on geography so to take location into account, spatial modeling will be included
using the census bureau regional breakdown (“Geography Atlas). We choose to use the
further divisional breakdown within the regions for more concise modeling purposes. The
4 regions (and divisions) used were: Northeast (New England division and Mid-Atlantic
division), Midwest (East-North Central division and West-North Central division), South
(South-Atlantic division, East-South Central division and West-South Central division)
and the West region (Mountain division and Pacific division).
5.3.5 Validation Analysis
To assess and validate the results, we used a 10-fold cross validation technique
(Kohavi) where we assigned each county a number at random and partitioned out 10% of
the counties into 10 separate groups (approximately 311 counties per partition) and then
we ran 10 models where one partition is left out of each model (called the validation or
testing set), and the model is run with the remaining partitions (called the training set).
The prediction for each county is made from the model where the county in not included.
This is commonly referred to as out-of-sample (oos) prediction. Proper validation and
estimation of the out-of-sample error is based on the residuals for each county in the
dataset, estimated as the difference between observed and oos predicted HIV rates. Root
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mean-squared-error (RMSE), which is analogous to the standard deviation, is estimated
then as the square-root of the average squared residual.
In addition to the 10-fold cross validation, we conducted loess smoother statistical
modeling (best fit line) comparing the observed counts with the predicted counts to look
at the bias on the individual level. We also calculated estimated residuals (the observed
counts reported from the county minus the SAE predicted counts) and plotted the
residuals for visual assessment. The closer the residual is to zero, the more precise the
model was in predicting the prevalent case count for that county. To take county
population size into account, we calculated the observed and predicted probabilities (the
observed and predicted counts divided by the total county population) and residual
probabilities. This allows us to calculate the observed (reported) and predicted
proportions of the total county population that has HIV. We then found a residual
proportion (observed minus predicted) or the difference of proportions for each county.
To assess the overall bias of the model, we produced the overall mean, 95% CI and the
standard deviation. In terms of geospatial assessment, we compared the SAE predicted
counts for those counties with no observed HIV count with the case count for counties
with population sizes similar (+/- 10%) to the average population size of the missing
counties across the country.
After assessing the validity of the predicted data, we examined the now completed
and updated data across the country and identified spatial patterns across the continental
U.S. in terms of hot-spots for HIV, focusing particularly on the areas with the new
estimated data has been filled in.
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5.4 Results
Overall, counts (and 95% CIs) were estimated for 677 counties across the
continental U.S. with the largest portion of missing counties coming from the West-North
Central (WNC) division (347 counties) which is in the Midwest region (displayed in
figure 5.1). The smallest portion of counties with missing counts came from the MidAtlantic (MA) and New England (NE) divisions (each missing 2), both in the Northeast
region. The average population size of the counties with missing counts in the WNC, MA
and NE in 2014 was: 8,665, 10,913 and 23,461.
The combination of reported HIV prevalent case counts, and SAE predicted
counts for the missing counties are displayed in figure 5.2. Most counties with estimated
counts largely fell into either quintile 1 or 2 and were located in the Midwest, West and
parts of the Southern region.
Overall, there are major pockets of counties in the highest HIV prevalence
quintiles (4 and 5) along the Eastern and Western coasts parts of the South, particularly in
the Deep South in states such as Florida and the Carolinas. The more inland
geographically, the less frequency of counties in the higher quintiles though the south had
a relatively steady pattern of HIV prevalence throughout, indicating the major HIV issues
in the region. There were a few outliers in the Midwest region of counties without
reported HIV prevalence that had a predicted HIV prevalence in the 3rd, 4th and 5th
quintile, particularly in South Dakota. Figure 5.3 displays the SAE estimated HIV
prevalent cases for counties with observed cases reported by the CDC to the AIDSVu
website. Similar to figure 5.1, our model estimated higher HIV prevalence along the east
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Figure 5.1 Quintile Map of Reported Prevalent HIV Counts by County, 2014
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Figure 5.2 Quintile Map of Reported and SAE Estimated Prevalent
Counts by County, 2014

89

and west coasts and across the U.S. south. The counties more inland had lower levels of
HIV prevalence in both the map displaying the reported prevalence and the one
displaying the SAE predicted cases.
Similar to figure 5.2 that displayed HIV prevalent cases, figure 5.4 which displays
the HIV prevalence rates (per 100,000), shows higher prevalence rates along the eastern
and western coasts as well as across the U.S. South region. Lower prevalence rates are
apparent in the Midwestern region of the country. Also similar to figure 5.2, is that there
is a small apparent cluster of higher HIV prevalence rates inland in states such as New
Mexico and Colorado.

HIV Case Count
Missing

Increase

Quintile 1
Quintile 2
Quintile 3
Quintile 4
Quintile 5

Figure 5.3 Quintile Map of SAE Prevalent HIV Case Counts by County, 2014
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Figure 5.4 Quintile Map of Reported and SAE Estimated HIV Prevalence Rates
per 100,000 by County, 2014

40000
35000

SAE Predicted Count

30000
25000
20000
15000
10000
5000
0
0

10000

20000

30000

40000

50000

60000

Observed (Reported) Count

Figure 5.5 Observed (Reported) Prevalent HIV Case Count vs SAE Predicted Case
Count
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Validation of our model involved 10-fold cross validation, loess smoother
statistical modeling (best fit line), calculation of estimate residuals (observed counts
reported from the county minus the SAE predicted counts), plotting of the residuals,
calculation and mapping of the percent differences between the observed and predicted
counts for all counties with both values available. Figure 5.5 (above) displays the results
of the 10-fold cross validation technique, displayed as a scatterplot of the observed (xaxis) HIV prevalent cases in each county (that was reported to and released by AIDSvu)
compared to the predicted prevalent HIV case count estimated by our SAE model.
Further assessment of the cross-validation is shown in figure 6 (displayed below) through
a loess smoothing statistical modeling which created a line of best fit (smoothing
parameter=0.6) to assess the relationship between the observed and predicted counts and
assess an trends that may have been present.
Figure 5.7 displays the residuals (observed reported HIV count minus the SAE
predicted count) for each eligible county (has both an observed and predicted count)
plotting by its FIPS code. The closer the residual is to 0, the smaller the difference
between the reported prevalent HIV count and the predicted count for that county based
on the SAE model. The figure 5.7 scatterplot displays the clumping of residuals near the
zero-value line, showing the majority of observed case counts and predicted estimates to
be similar with a small amount of the 2,436 counties with residuals (having both an
observed and predicted count) straying farther away from zero.
Table 5.1 further illustrates that point as the mean of the residuals was 33.46
(95%CI= 6.81, 60.12) with a root mean-squared-error (RMSE) of 670.89, which was due
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in part to the counties with much larger populations and hence larger residuals, as had
been expected prior to analysis.
The counties with the largest residual were Kings County, NY (population size of
2,646,735; observed case count of 27,002; residual of +16701.31), Los Angeles County,
CA (population size of 10,170,292; observed case count of 47,664; residual of +9930.07),
Dekalb County, GA (population size of 734,871; observed case count of 6,638; residual
of -8483.41) and Cook County, IL (population size of 5,238,216; observed case count of
24,996; residual of -7423.76). On the opposite end, 657 counties had residuals of +/- 5
cases (~27%) and 1,027 of the counties had residuals of +/- 10 cases (~42%).

Figure 5.6 Loess Smoother Modeling of Observed vs Predicted Prevalent
HIV Cases
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In terms of comparing the accuracy of the model to predict case counts for the
counties without observed counts which typically tend to be small due to the sparse
population size (average population of these counties is ~8.312), the average residual for
counties with observed case counts of 20 or less, was -5.13. The average residual for
counties with observed counts and have population sizes within 10% of the average
population size of missing counties was -2.19.
Figure 5.8 displays the residual proportions or the difference between the
observed (reported) proportions of the total population for each county that has HIV
compared to the predicted proportion (through use of SAE estimated case counts) of the
same population that has HIV. The map brings to focus a few outliers although
regionality largely provides large indicators for the accuracy of the model.

Figure 5.7 Residuals plotted by County FIPS Code
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Particularly across the Midwest region, the counties are mostly clustered between
quintiles 1 and 3 (denoting smaller differences between the observed and SAE predicted
proportions). The largest contrast between observed and predicted proportion which
occurred in Tallahatchie County, Mississippi (predicted=2.64%, observed=0.16%) and
Union county, Florida (predicted=0.40%; observed=2.09%).

Table 5.1 Mean (95% CI) and Standard Deviation of the Residuals

Mean (95% CI)
33.46 (6.81,60.12)

Root mean-squared-error (RMSE)
670.89

Increase

Figure 5.8 Residual Proportions of Population with HIV at the County Level, 2014
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As a whole, the greater differences in observed and predicted proportions were
concentrated in the South and Northeast where there are generally larger and more
diverse population sizes. There are also pockets of higher proportional differences in the
more urban settings within the West region. The areas with the smaller population sizes
tended to have smaller differences between the observed and predicted proportions of
HIV as had been expected.
The results indicate that as population size increases (and diversity of the
population demographics increases) our predictive model is less accurate when compared
to predicting prevalence in smaller counties with more homogenous population
demographics. The results do align with our objective of predicting HIV burden in
counties without previously reported prevalence. Population sizes in those publicly
unreported counties tended to be small and more rural, which matches well with the
strengths of our predictive model.
5.5 Discussion
We used small area estimation modeling techniques to estimate prevalent HIV
case counts for counties where the prevalence was unreported for 2014 (either missing or
suppressed). Due to the nature of the counties with missing data (majority are counties
with sparse population sizes) and auxiliary data available to us (all area-level), we
utilized a Poisson regression model with fixed and random effects. Over half of the
missing counts came from counties in the Midwest region of the U.S. (59%), due in part
to the data suppression of HIV prevalence in counties (mostly rural) with sparse
populations and potentially small HIV case counts but also due in part to missing reports
and it is not noted if the data for that county is suppressed or simply gone unreported. It is
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to be noted that previous literature (Vyayaharkar; Hall et al.) has indicated that the
number of HIV cases proportional to population size in rural settings can be just as great
as the burden of HIV in more populated areas and hence the need to report those numbers
for surveillance purposes.
The majority of the counties that our model estimated HIV prevalence for that did
not have it previously reported, fell within the lower quintiles (lower HIV burden).
However, there were a few outlier counties particularly in South and North Dakota. Sioux
county, North Dakota for example was placed in quintile 5 (highest level of HIV burden)
in part due to high rates of co-morbidities (syphilis and chlamydia incidence rates) and
also has high percentage of American Indians which is a race that research has shown
infectious diseases to have a significant effect in the cause of morbidity (Cheek et al.).
Pennington and Walworth Counties (both in South Dakota) also had high levels of comorbidities and Pennington in particular has one of the largest counties population wise
in the state. These results could indicate that population size and burden of HIV comorbidities are strong drivers in our SAE model.
Our study had a few strengths and limitations. A strength of our study was the
utilization of readily available secondary area-level covariate data, all of which are
pertinent-HIV risk indicators. Due to the regional characteristics of HIV, we also used
spatial factors such as regionality to borrow further strength for our model. While a
limitation was the lack of individual unit-level covariate data, our unique approach does
provide a basis for future studies to utilize secondary, area-level data for predictive
modeling of health outcomes, if individual level data is not readily available. A limitation
in our dataset was the lack of data on intravenous drug use (IDU) as it would have
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provided further strength to our model given the strong relationship between HIV high
risk behaviors such as IDU and HIV burden. Another strength of our study was our use of
multiple validation techniques to assess the precision of the data. We believe that the
validation analyses strengthened the confidence in our SAE model to estimate HIV case
counts, particularly in areas with missing data.
Our study was done to provide a more complete picture of the prevalence of HIV
across the country and identify communities in need of targeted intervention in the future.
The results from this study can be of use to those who have never had concise data on
these areas before such as public health practitioners who can use the data when
determining outreach efforts. Policy makers may use this data to help drive funding
decisions for areas that may have potential for future HIV outbreaks based on current
data. Organizations such as AIDSVu and others who track and map HIV prevalence, can
replicate the estimation process and update the prevalence for missing counties, annually.
5.6 Conclusion
To properly assess the state of HIV burden across the country, a complete picture
of the data is needed. Our study utilized unique small area estimation statistical
methodology to provide a projected picture of the burden of HIV in areas where data was
not publicly available. Our findings can be used by policy makers and public health
professionals in creating targeted outreach efforts, policies and to drive potential funding
of interventions. Future steps involve further exploration of this data through geospatial
assessment to identify clusters and hot-spots of HIV prevalence across, counties, states,
regions and nationwide.
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CHAPTER 6

TRENDS IN HIV TESTING AMONG U.S. ADULTS: AN ANALYSIS OF
2011-2017 BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM
DATA3

3

Khan S, Torres M, Olatosi B, McLain A, Eberth J. to be submitted to AIDS and Behavior
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6.1 Abstract
We used 2011-2017 BRFSS data to examine HIV testing temporal trends and
assess relationships between key individual factors and the likelihood of reporting as ever
tested for HIV and tested within the past year. Our analysis included sub-analyses for
years data was collected on sexual orientation and HIV high risk behaviors. Results
showed an average of 35.01% reporting ever being tested for HIV, with an average
annual percent change (APC) of +1.20% from 2011 to 2017 though percentages within
the past year slightly declined (-0.29% APC). Females, individuals with health insurance,
those who identify as lesbian/gay and partake in high risk behaviors were more likely to
report being tested for HIV compared to males, individuals without insurance, identify as
straight and do not partake in high risk behaviors. Our findings indicate the need for
further targeted interventions and outreach efforts to increase HIV testing throughout the
U.S.
Key words: HIV testing, BRFSS, HIV, Screening
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6.2 Introduction
Organizations such as the Centers for Disease Control and Prevention (CDC) and
the U.S. Preventative Services Task Force (USPSTF) have long called for the reduction
of barriers to HIV testing (“HIV Surveillance Report”; “Final Recommendations
Statement”). Still, a reported 40% of new HIV infections are transmitted by people living
with HIV (PLWH) who are unaware of their status (“HIV Surveillance Report”). Not
knowing ones’ HIV status is highly problematic because those living with undiagnosed
HIV infection are more likely to transmit the infection and have poorer health outcomes
(Oppong). A targeted focus on increasing HIV testing rates across the country is needed,
particularly among vulnerable populations such as racial/ethnic and sexual minorities and
those living in rural areas where late HIV diagnosis is an issue (Adler; Trepka). In 2006,
the CDC introduced an HIV testing “opt-out approach” recommendation (Galletly) to
increase HIV testing rates nationally, however results showed a temporary increase in
rates before leveling out again among certain populations (Ford). The recommendations
have also not helped alleviate stigma associated with HIV testing (Mahajan). Poor HIV
testing rates lead to late diagnosis and lower CD4+ counts at time of diagnosis which are
indicators of advanced progression of the disease which lower chances of successful viral
load suppression (Trepka).
Continuous monitoring of HIV testing rates is necessary to assess and identify
disparities that can be targeted through policy or programmatic changes. However, there
are gaps in the literature exist for HIV testing utilization across the country. Previous
literature has mostly either examined testing in a specific location (Ansa), a specific age
bracket (Ford) or how specific policy changes affect testing (Gaines). There haven’t been
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any recent studies that have examined HIV testing rates across the country, across all
ages and over a considerable period of time. Of the few studies examining HIV testing
across the U.S., most only do so using a single year of the survey data (Henderson),
limiting our ability to identify trends in HIV testing rates over time and explore policy,
environment, or socio-demographic drivers. Due to the one-year time frames in past
studies, there hasn’t been much peer-reviewed literature that tracked the changes in rates
due to efforts to increase HIV testing or the lack of a change in vulnerable populations.
This is of particular importance in areas with historically lower rates of testing such as
the south and among minorities to see if HIV testing is improving or not (Trepka).
The purpose of this study is to explore HIV testing percentages and individuallevel determinants among different population subgroups over time using self-reported
BRFSS data from 2011-2017. Based on prior work (Ford; Gaines), we hypothesize that
utilization of HIV testing will be lower among minority groups, individuals without
insurance and among males in general. While there have been major strides made in
increasing access to HIV testing through national interventions and technological
advancements, such as using social media to promote HIV testing (Cao), the progress is
not shared equally across all segments of the U.S. population. Even among minority
groups, the burden of disease generally follows socioeconomic lines, with the greatest
burden observed among the poor (Pellowski). The results from this study will provide
further insight on the current state of the utilization of HIV testing resources across the
U.S. and chart the progress or lack thereof regarding self-reported testing rates among
different, vulnerable subpopulations.
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6.3 Methods
6.3.1 Study Design
This is a cross-sectional study done by analyzing self-reported HIV testing data
from the 2011-2017 Behavioral Risk Factor Surveillance System (BRFSS) which is a
nationally representative survey. It is the largest continually conducted health survey in
the world and collects data from over 400,000 adults annually.
6.3.2 Sample and Data Source
BRFSS is a nationally representative phone-based survey for all 50 states and the
District of Columbia and comprehensively explores health behaviors, chronic health
conditions and healthcare use. Since 2011, the sampling methodology for the BRFSS has
been altered (“Methodological Changes”), including an update to its data weighting
methodology and incorporating cellular phone-based surveying. From 2011-2017, the
BRFSS has surveyed over 3 million adults across the nation. Of those, our study included
all who answered the question “Have you ever been tested for HIV, excluding tests as
part of a blood donation?” and excluded those who refused or did not choose to answer
the HIV-related questions.
6.3.3 Measures
The main dependent variable looked at was overall self-reported HIV testing
percentages which was assessed via the set of questions asked in the 2011-2017 BRFSS
about if the participant had ever been tested for HIV, excluding tests as part of a blood
donation. If the participant answered ‘yes’, further questioning assessed the date and
location of the last HIV test. Secondarily, we are interested in assessing past-year HIV
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testing percentages. We created a binary variable (yes vs no) identifying if they had been
tested within 12 months prior to the interview to assess this objective based on reported
date of last HIV test taken.
The independent variables include demographic data and health behavior
indicators which were collected at the individual level. Data on variables associated with
HIV testing were collected across the targeted 7-year range of surveys and included: age
in years (18–24, 25–34, 35–44, 45–54, 55–64, or 65+), sex (male or female),
race/ethnicity (non-Hispanic (NH) white, NH black, NH Asian, NH Native
American/Alaskan, NH Native Hawaiian/Pacific Islander or Hispanic), educational
attainment (<high school, high school graduate, some college and college graduate),
current employment status (employed, self-employed, out of work <1 year, out of work>
1 year, homemaker, student, retired or unable to work) annual household income in
United States Dollar (USD (<$25,000, $25,000-$50,000, $50,000-$75,000 and
$75,000+)), marital status (married, divorced, widowed, separated, or never married,);
healthcare coverage (yes/no). Risky health behavior measures were also included such as
being classified as a binge drinker (yes/no), current smoking status (everyday, some days
or not at all) and engaging in any of the following HIV risk behaviors in the past year
(HIV high-risk situations (yes/no)) - use of intravenous drugs, treatment for sexually
transmitted disease, giving or receiving money or drugs for sex, or having anal sex
without a condom. The list of the exact BRFSS survey questions and answer choices used
for each variable is provided in the appendix C.
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6.3.4 Analysis
We obtained the weighted percentages of respondents who had ever been tested
for HIV stratified by the socio-demographic and health behavior indicators listed above.
Additionally, we calculated the average weighted percentage and average annual percent
change over the 7-year period to assess reporting trends during that time. We ran
regression analyses to assess the association between ever being tested for HIV and the
socio-demographic variables listed above, using data pooled from 2011-2017. We also
ran a regression model to assess the association between being tested for HIV within the
past year and socio-demographic variables. The estimates in both regression models were
adjusted for by the demographic variables and selected health behavior indicators (age,
gender, race/ethnicity, educational attainment, current employment status, annual
household income, healthcare insurance coverage, marital status, binge drinker status and
smoking status). We also conducted sub-analyses using the populations from years that
the BRFSS collected data on sexual orientation (2014-2017) and a separate analysis using
the years that the BRFSS collected data on HIV high risk activity exposure (from 20112012 and 2016-2017).
To account for differences in data collection (nonresponse, respondent selection,
and telephone non-coverage), the data was weighted using built-in calculated weights
from the BRFSS dataset (“Weighting BRFSS Data”). Odds ratios, 95% confidence
intervals and p-values will be obtained from the regression analyses. Regression analyses
were run using survey logistic modeling as opposed to standard logistic regression due to
the complex sampling design of the survey (Berglund).
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6.4 Results
Across the U.S., an average of 36.07% of respondents reported having ever been
tested for HIV, from 2011 to 2017. The weighted percentages of those, by year of
interview, the average percentage across all 7 years and the APC are shown in table 6.1.
All variables included in table I had a significant effect on the dependent variable of
having ever been tested for HIV (P<0.0001). The weighted proportion of those who
reported ever being tested for HIV has increased from 2011 to 2017 (35.92% to 38.45%).
Among age categories, the 25-34 age group had the highest reported average weighted
percentages of ever having been tested (53.34%), though there was a slight decline in the
percentage ever tested over the 7-year period (-2.08% average annual percent
change/APC). A weighted average of 44.92% of those classified as binge drinkers (males
having five or more drinks on one occasion, females having four or more drinks on one
occasion) reported as ever having an HIV test as opposed to 34.88% of those classified as
non-binge drinkers. College graduates had higher reported percentages of ever having
been tested for HIV from 2011-2017 (38.67% average weighted percentage) while H.S.
graduates had the highest average APC (+8.85%).
A greater weighted proportion of females (37.12%), NH blacks (58.83%), persons
with < $25,000 annual median household income, respondents without health insurance
(42.82%) and those that are separated but not divorced (53.12%) reported having ever
been tested for HIV from 2011 to 2017 than the other subcategories. A higher weighted
proportion of those self-reporting as gay/lesbian reported having ever having been tested
for HIV compared to those self-classified as straight (67.88% vs 35.01%).
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Table 6.1. Weighted Proportions to Have Ever Been Tested for HIV Stratified by Select Characteristics (n=Unweighted Frequency),
2011-2017

Category
Overall
Yes

2011

2012

2013

2014

2015

2016

2017

AVG
(%)

35.92
(n=133,239)

35.22
(n=129,846)

35.86
(n=132,093)

34.32
(n=117,007)

36.10
(n=113,779)

36.60
(n=136,267)

38.45
(n=127,137)

36.07

33.59
(n=7,246)
55.29
(n=24,871)
51.81
(n=31,248)
37.89
(n=31,290)
23.86
(n=25,097)
9.94
(n=13,487)

31.63
(n=7,694)
53.43
(n=23,929)
51.74
(n=29,449)
37.82
(n=29,397)
25.35
(n=24,293)
11.49
(n=15,084)

31.47
(n= 7,797)
54.00
(n=23,591)
52.86
(n=28,773)
40.13
(n=29,914)
26.43
(n=25,457)
11.97
(n=16,561)

28.75
(n=6,283)
51.50
(n=19,905)
49.86
(n=24,650)
38.66
(n=26,493)
26.15
(n=23,366)
12.46
(n=16,310)

29.75
(n=6,059)
52.96
(n=18,878)
53.63
(n=23,539)
42.23
(n=25,878)
28.01
(n=23,211)
12.88
(n=16,214)

29.58
(n=7,116)
52.04
(22,917)
54.13
(27,284)
43.36
(30,330)
29.44
(n=27,759)
13.82
(20,861)

31.1
(n=7,038)
54.14
(n=21,301)
56.96
(n=25,051)
46.49
(n=27,861)
31.89
(n=26,082)
14.92
(n=19,804)

34.27
(n=107,232)
46.23
(n=24,195)

34.13
(n=105,655)
43.94
(n=22,079)

35.11
(n=108,117)
44.06
(n=21,982)

33.7
(n=96,210)
42.81
(n=18,898)

34.95
(n=93,343)
44.37
(n=18,601)

35.42
(n=110,652)
45.22
(n=23,049)

36.61
(n=102,648)
47.83
(n=22,282)

34.15
(n=10,825)
31.64
(31,272)
38.98
(38,912)
38.31
(52,035)

34.11
(n=10,478)
31.32
(n=31,081)

35.07
(n=10,415)
31.39
(n=30,723)
38.06
(n=38,962)
38.82
(n=51,743)

33.49
(n=8,786)
30.87
(n=26,837)
36.59
(n=34,127)
36.44
(n=47,016)

35.22
(n=8,287)
32.04
(n=25,542)
37.73
(n=33,079)
38.93
(n=46,591)

35.51
(n=10,531)
33.1
(n=32,373)
38.47
(n=39,505)
38.83
(n=53,556)

37.02
(n=8,764)
34.44
(n=29,034)
40.44
(n=37,194)
41.01
(n=51,845)

Average
%
Change
7.04

Age

Pvalue
<.001

<.001
18-24
25-34
35-44
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45-54
55-64
65+

30.84

-7.41

53.34

-2.08

53.00

9.94

40.94

22.70

27.30

33.65

12.50

50.10

Binge Drinkers

<.001
No
Yes

Educational
Attainment
Less than H.S.
H.S. Graduate
Some College
College Graduate

34.88

6.83

44.92

3.46
<.001

36.9 (n=37,695)
38.32 (50,389)

34.94

8.40

32.11

8.85

38.17

3.75

38.67

7.05

Employment Status
Employed
Self-Employed
Out of Work> 1 year
Out of Work< 1 year
Homemaker
Student
Retired
Unable to Work

<.001
40.5
(n=68,521)
39.01
(n=11,593)
45.41
(n=6,460)
47.72
(n=5,688)
36.27
(n=8,876)
32.98
(n=4,018)
12.42
(n=14,285)
44.58
(n=13,398)

39.66
(n=66,482)
37.97
(n=11,400)

30.26 (n=4,203)
13.99
(n=14,954)
45.45
(n=13,575)

40.84
(n=67,411)
38.82
(n=11,768)
46.1
(n=5,407)
47.89
(n=5,052)
37.07
(n=7,794)
30.09
(n=4,064)
14.11
(n=16,030)
45.08
(n=14,045)

39.06
(n=59,812)
36.56
(n=10,439)
47.01
(n=3,959)
47.22
(n=3,884)
33.89
(n=6,924)
27.58
(n=3,199)
14.59
(n=15,632)
45.56
(n=12,676)

41.66
(n=58,582)
38.91
(n=10,188)
45.67
(n=3,506)
49.07
(n=3,491)
37.9
(n=6,723)
27.62
(n=3,204)
14.9
(n=15,510)
46.07
(n=11,846)

42.28
(n=68,787)
39.59
(n=12,651)
46.93
(n=3,933)
47.75
(n=4,143)
37.42
(n=7,462)
27.26
(n=3,506)
16.17
(n=20,016)
46.99
(n=14,834)

44.82
(n=65,107)
42.26
(n=11,893)
46.17
(n=3,964)
51.04
(n=3,835)
38.22
(n=6,462)
28.87
(n=3,536)
17
(n=18,322)
47.86
(n=13,111)

34.27
(n=52,987)
36.11
(n=76,859)

34.40
(n=54,813)
37.23
(n=77,280)

33.04
(n=48,881)
35.54
(n=68,126)

34.94
(n=48,877)
37.19
(n=64,902)

35.65
(n=59,993)
37.49
(n=76,256)

37.48
(n=57,178)
39.36
(n=69,865)

63.74
(n=10,156)
36.83
(n=116,221)
29.96
(n=60)
44.46
(n=22,224)
39.8
(n=20,808)
37.52
(n=14,260)

45.57 (n=5,650)
46.82 (n=5,125)
35.77 (n=8,102)

41.26

10.67

39.02

8.33

46.12

1.67

48.22

6.96

36.65

5.38

29.24

-12.46

14.74

36.88

45.94

7.36

Gender

<.001
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Male
Female
Risky Health
Behavior
Exposure*

34.84
(n=52,943)
36.94
(n=80,296)

34.95

7.58

37.12

6.55

<.001
Yes
No
Don't Know

65.13
(n=5,973)
36.44
(n=126,576)
36.08
(n=90)

63.94 (n=6,355)
34.89
(n=122,763)
30.83
(n=81)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

63.8
(n=10,347)
35.47
(n=124,963)
41.28
(n=102)

41.93
(n=27,481)
36.25
(n=23,344)
34.19
(n=15,858)

41.22
(n=27,287)
36.03
(n=22,714)
33.64
(n=15,434)

41.57
(n=27,560)
36.68
(n=23,113)
35.39
(n=15,701)

40.62
(n=22,855)
36.1
(n=20,199)
33.66
(n=13,845)

42.17
(n=20,214)
37.43
(n=18,536)
35.93
(n=33,951)

42.13
(n=24,776)
37.99
(n=22,884)
36.53
(n=15,756)

64.15

-2.13

35.91

1.07

34.54

-16.96

Income

<.001
< $25,000

$25,000-$50,000
$50,000-$75,000

41.61

6.03

37.18

9.79

35.27

9.74

>$75,000
Have any type of
Insurance
Yes
No
Marital Status
Married
Divorced
Widowed
Separated
Never Married
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Race/Ethnicity
NH White
NH Black
Hispanic

37.68
(n=35,823)

35.69
(n=34,639)

36.89
(n=35,472)

34.87
(n=33,513)

37.35
(n=6,982)

37.88
(n=39,321)

39.8
(n=38,565)

34.34
(n=112,450)
43.41
(n=20,497)

33.73
(n=109,572)
42.32
(n=19,992)

34.27
(n=111,497)
44.11
(n=20,271)

33.33
(n=103,75)
41.23
(n=12,953)

35.31
(n=102,708)
42.81
(n=10,745)

35.92
(n=123,102)
42.44
(n=12,767)

37.89
(n=114,330)
43.44
(n=12,457)

31.54
(n=64,116)
44.74
(n=24,672)
13.82
(n=6,667)
54.47
(n=4,885)
42.1
(n=26,168)

30.57
(n=60,935)
45.05
(n=23,873)

41.2 (n=26,862)

32.22
(n=61,842)
44.71
(n=24,710)
15.31
(n=6,968)
52.55
(n=4,765)
41.25
(n=26,954)

30.37
(n=55,830)
43.52
(n=21,303)
15.7
(n=6,333)
51.78
(n=3,963)
39.6
(n=23,625)

32.39
(n=54,474)
45.75
(n=20,212)
15.91
(n=5,862)
53.38
(n=3,884)
40.93
(n=23,012)

32.84
(n=63,599)
45.14
(n=24,227)
16.8
(n=7,504)
52.72
(n=4,710)
41.44
(n=28,325)

34.82
(n=58,754)
47.67
(n=22,733)
17.96
(n=6,890)
55.61
(n=4,175)
43.02
(n=27,121)

29.91(n=85,957)
59.68
(n=19,322)
40.84
(n=13,202)

30.76
(n=88,514)
57.98
(n=17,946)
41.85
(n=13,718)

29.45
(n=77,890)
58.3
(n=16,202)
38.87
(n=12,234)

31.06
(n=75,458)
58.88
(n=15,121)
42.48
(n=12,933)

31.65
(n=89,753)
59.49
(n=19,109)
41.7
(n=15,277)

33.24
(n=83,525)
61.11
(n=16,933)
44.87
(n=14,219)

42.49 (n=2,503)

41.36
(n=2,722)

42.18
(n=2,482)

46.07
(n=2,373)

44.52
(n=2,700)

46.9
(n=3,183)

27.08
(n=2,006)
38.31
(n=481)

22.67
(n=1,800)
40.00
(n=502)

23.45
(n=2,015)
38.06 (n=387)

24.15
(n=2,117)
36.47
(n=420)

27.2
(n=2,056)
49.61
(n=486)

33.23
(n=37,057)
69.52
(n=1,176)

34.91
(n=43,433)
64.66
(n=1,453)

34.34
(n=55,144)
65.92
(n=1974)

37.56
(n=58,247)
71.42
(n=2,084)

5.63
<.001

34.97

10.34

42.82

0.07
<0.01

15.19 (n=6,904)
51.36 (n=4,568)

32.11

10.40

45.23

6.55

15.81

29.96

53.12

2.09

41.36

2.19
<.001

31.26
(n=90,004)
59.59
(n=18,459)
40.26
(n=13,854)

NH American
Indian/Alaskan

40.76
(n=2,552)

NH Asian

25.03
(n=1,966)
43.1
(n=559)

NH Native
Hawaiian/Pacific
Islander
Sexual
Orientation**

37.17

23.94 (n=2,048)
39 (n=555)

34.42

6.33

58.83

2.55

42.16

11.45

43.14

15.06

28.23

8.67

44.39

15.10

<.001

Straight

N/A

N/A

N/A

Lesbian/Gay

N/A

N/A

N/A

35.01

13.03

67.88

2.73

Bi-sexual

N/A

N/A

N/A

Other

N/A

N/A

N/A

Not Sure
Current Smoking
Frequency
Every Day

N/A

N/A

N/A

52.00
(n=935)
33.28
(n=116)
28.99
(168)

47.58
(n=23,180)
48.34
(n=8,602)
33.18
(n=35,110)

47.47
(n=21,430)
48.47
(n=8,703)
32.71
(n=34,371)

47.88
(n=21,415)
47.74
(n=8,519)
33.86
(n=35,189)

47.45
(n=17,915)
46.54
(n=7,560)
32.73
(n=31,402)

Some Day
Not At All

55.88
(n=1,181)

30.09 (n=401)

57.02
(n=1,865)
33.61
(n=263)
26.14
(n=456)

56.91
(n=2,021)
34.16
(n=273)
27.64
(n=446)

49.08
(n=16,610)
49.73
(n=7,190)
34.63
(n=30,681)

49.65
(n=20,654)
49.94
(n=8,455)
35.85
(n=36,756)

51.47
(n=18,587)
51.93
(n=8,115)
37.32
(n=34,275)

28.46 (n=157)

55.45

9.44

32.38

2.64

28.22

-4.66
<.001

* High Risk Behavior Activity Question not asked in BRFSS, 2013-2015
**Sexual Orientation Question not asked in BRFSS, 2011-2013

48.65

8.18

48.96

7.43

34.33

12.48
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Among those that responded as having ever been tested for HIV in the BRFSS
survey from 2011 to 2017, an average of 14.43% of them also self-reported as having
their last HIV test within 12 months prior to their interview date (table II). All variables
included in table 5 had a significant effect on the dependent variable of having been
tested for HIV within 12 months prior to their interview date (P<0.0001).
Based on their responses, those who were 1) not classified as a binge drinker, 2)
between the age of 18-24, 3) with some college experience, 4) females, and 5) report
<$25,000 median household income had a higher average proportion self-report as
having their last HIV test on a date within 12 months of their interview date compared to
the other subgroups in their respective categories. Also, those who reported as currently
smoking (every day or some days) averaged a higher proportion who received their last
HIV test within 12 months of their interview date compared to those who were surveyed
and reportedly did not smoke at all.
Among those who responded to the question regarding sexual orientation and
reported as having ever been tested for HIV, the highest proportion reporting a HIV test
within the past 12 months was among those who self-identified as Bi-sexual (22.81%
average) lesbian/gay (22.16% average) compared to any other sexual orientation. NHblacks also reported receiving a HIV test within 12 months of their interview date at a
higher weighted proportion (21.15% weighted average) compared to NH-whites (11.49%
weighted average) and Hispanics (16.31% weighted average). For employment
categories, the largest average weighted proportion who reported receiving their last HIV
test within the past 12 months was among students (26.14%), though the largest positive
APC was among the self-employed (+8.92%).
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Table 6.2 Weighted Proportions to Have Been Tested for HIV within the Past-Year Stratified by Select Characteristics,
2011-2017
Category

2011

2012

2013

2014

2015

2016

2017

AVG (%)

Avg % Change

Yes

15.1

14.44

14.91

14.01

14.82

13.33

14.42

14.43

-4.50

18-24
25-34
35-44
45-54
55-64
65+

28.92
18.6
12.07
10.8
8.85
8.7

28.8
18.17
12.17
9.59
8.2
7.71

30.46
19.71
12.35
9.46
8.73
7.52

27.43
18.72
11.81
9.24
8.59
6.83

29.57
18.89
13.83
10.16
8.73
7.16

26.12
18.1
11.7
9.05
7.73
7.04

28.19
19.64
12.53
10.05
9.29
7.33

28.50
18.83
12.35
9.76
8.59
7.47

-2.52
5.59
3.81
-6.94
4.97
-15.75

No
Yes

14.59
16.82

14.08
16.04

14.42
16.83

13.37
16.34

14.62
15.74

12.89
15.32

14.05
15.65

14.00
16.11

-3.70
-6.96

Less than H.S.
H.S. Graduate
Some College
College Graduate

17.14
15.95
15.41
12.91

15.13
15.24
15.11
12.63

16.19
15.26
16.47
12.18

15.36
15.18
14.88
11.29

14.46
16.47
15.49
12.87

11.68
14.85
14.38
11.62

14.26
14.71
16
12.55

14.89
15.38
15.39
12.29

-16.80
-7.77
3.83
-2.79

Employed
Self-Employed
Out of Work> 1 yr
Out of Work< 1 yr
Homemaker
Student
Retired
Unable to Work

14.81
10.88
17.42
21.48
12.32
25.82
9.28
14.34

14.34
11.75
15.91
19.55
11.1
27.69
8.19
13.51

14.66
13.02
17.06
20.38
12.87
27.11
7.83
14.57

14.17
11.65
17.6
19.06
10.45
24.62
7.12
13.79

14.98
13.26
15.86
20.82
12.01
25.56
8.08
14.77

13.91
10.88
17.02
16.81
9.95
24.87
7.35
11.69

14.74
11.85
14.9
20.15
10.98
27.31
8.92
13.81

14.52
11.90
16.54
19.75
11.38
26.14
8.11
13.78

-0.47
8.92
-14.47
-6.19
-10.88
5.77
-3.88
-3.70

15.3

14.62

15.62

14.64

14.94

13.97

14.78

14.84

P-Value

Overall

Age

<.0001

Binge Drinkers

<.0001
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Educational Attainment

<.0001

Employment Status

<.0001

Gender

0.0172
Male

-3.40

14.93

14.28

14.3

13.45

14.7

12.75

14.11

14.07

-5.49

Yes
No
Don't Know

22.49
14.59
34.62

22
13.9
11.11

N/A
N/A
N/A

N/A
N/A
N/A

N/A
N/A
N/A

22.15
12.31
14.16

25.01
13.2
13.87

22.91
13.50
18.44

11.20
-9.53
-59.94

< $25,000
$25,000-$50,000
$50,000-$75,000
>$75,000
Have any type of Insurance
Yes
No
Marital Status
Married
Divorced
Widowed
Separated
Never Married
Race/Ethnicity
NH White
NH Black
Hispanic
NH American Indian/Alaskan
NH Asian
NH Native Hawaiian/Pacific Islander
Sexual Orientation**
Straight
Lesbian/Gay
Bi-sexual
Other
Not Sure

17.65
17.52
15.55
11.59

17.09
15.83
15.34
11.7

18.41
16.53
14.65
11.05

16.52
16.36
14.28
10.47

17.34
16.5
16.6
11.62

16.02
15.45
14.14
10.38

17.69
16.96
14.72
11.41

17.25
16.45
15.04
11.17

0.23
-3.20
-5.34
-1.55

14.74
16.26

14.2
15.18

14.74
15.43

13.64
15.91

14.81
14.71

13.3
13.59

14.38
14.58

14.26
15.09

-2.44
-10.33

10.32
14.22
9.5
19.33
21.99

9.48
13.28
9.97
17.52
21.93

10.06
12.93
9.28
17.82
24.18

9.39
12.49
8.56
16.55
22.2

9.83
13.93
10.71
16.47
23.33

9.25
12.6
8.7
15.31
20.37

9.97
13.42
9.76
16.02
22.22

9.76
13.27
9.50
17.00
22.32

-3.39
-5.63
2.74
-17.12
1.05

11.96
22.05
18.38
14.53
22.12
16.54

11.21
21.23
16.66
14.09
26.58
16.73

11.9
20.89
17
16.73
13.44
18.85

11.01
21.61
15.01
18.36
11.51
16.66

12.08
22.29
15.74
14.03
12.98
26.38

10.47
19.4
15.37
13.67
13.53
14.81

11.82
20.61
16.04
15.45
14.87
24

11.49
21.15
16.31
15.27
16.43
19.14

-1.17
-6.53
-12.73
6.33
-32.78
45.10

N/A
N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A
N/A

15.17
22.51
26.50
20.88
21.86

15.59
22.86
23.07
16.44
12.15

13.07
24.01
18.35
11.52
12.34

13.78
19.26
23.35
20.21
14.89

14.40
22.16
22.82
17.26
15.31

-9.16
-14.44
-11.89
-3.21
-31.88

Female

Risky Health Behavior Exposure*

<.0001

Income

<.0001

<.0001

<.0001
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<.0001

<.0001

Current Smoking Frequency

<.0001
Every Day
Some Day
Not At All

15.43
17.45
12.13

14.32
15.75
11

15.9
18.66
10.95

15.4
17.66
10.58

15.15
17.17
11.32

* High Risk Behavior Activity Question not asked in BRFSS, 2013-2015
**Sexual Orientation Question not asked in BRFSS, 2011-2013

13.08
16.27
10.78

14.67
16.36
11.07

14.85
17.05
11.12

-4.93
-6.25
-8.74
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The results from the multivariate logistic regression analysis are displayed in table
6.3, which assessed associations between the pooled data on the demographic variables
from 2011 to 2017 (provided in table 6.1) and having ever been tested for HIV, after
model adjustment (as noted in table III, sexual orientation and high-risk behaviors were
excluded due to data missing for certain years). All variables entered had a significant
effect on the final model. The likelihood of ever being tested for HIV was inversely
associated with levels of education lower than a college degree (p<0.01 for all three
levels- no H.S. education, H.S. degree and some college) as well as lack of health
insurance (OR=0.84; 95%CI= 0.82, 0.87; p<0.0001) and not being classified as a binge
drinker (OR=0.96; 95%CI= 0.94, 0.99); p= 0.0038).
Non-Hispanic blacks (OR=2.53; 95%CI= 2.43, 2.62; p<0.0001), females
(OR=1.19; 95%CI= 1.16, 1.21; p<0.0001), those with less than $25,000 in median
household income (OR=1.07; 95%CI= 1.03, 1.11; p=0.0007), and those between the ages
of 25-34 (OR=6.70; 95%CI= 6.40,7.020; p<0.0001) were more likely to have reported
ever being tested for HIV than non-Hispanic whites, males, those who have a median
household income greater than $75,000 and those 65 and older. Daily smokers
(OR=1.15; 95%CI= 1.12, 1.18; p<0.0001) and those who were either divorced or
separated but not divorced (OR= 1.6 and p-value<0.0001 for both), were also more likely
to report having ever been tested for HIV than non-smokers and those that are married.
All variables entered except for gender and binge drinking status had a significant
effect in the final model. The likelihood reporting having been tested for HIV within the
past 12 months was negatively associated with level of educational attainment, with the
lowest likelihood being among those with less than a high school degree
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Table 6.3 Multivariate Logistic Regression Analysis Results of Demographic Variables Associated with Ever and
within Past-Year Testing of HIV, 2011–2017

Variable*

Odds
Ratio

Ever
95% Confidence
Limits

PValue

Odds
Ratio

<.0001
<.0001
<.0001

0.771
0.781
0.965
REF

Past-Year
95% Confidence
Limits

PValue

0.717
0.739
0.916

0.829
0.825
1.017

<.0001
<.0001
0.1783

1.017
1.197
1.275
1.043
1.033
0.826
1.322

1.182
1.416
1.508
1.276
1.258
1.007
1.5

0.0162
<.0001
<.0001
0.0055
0.0089
0.0675
<.0001

Educational Attainment
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Less than H.S.
HS Graduate
Some College
College Graduate
Current Employment Status
Employed
Self-Employed
Out of Work <1 year
Out of Work>1 year
Homemaker
Student
Retired
Unable to Work
Race/Ethnicity
NH White
NH Black
NH American Indian/Alaskan
NH Asian
NH Native Hawaiian/Pacific Islander
Hispanic
Gender
Male
Female
Have Health Insurance

0.607
0.628
0.866
REF

0.584
0.61
0.843

0.632
0.646
0.89

REF
1.158
1.273
1.292
1.168
1.013
0.906
1.48

1.114
1.205
1.223
1.114
0.943
0.873
1.427

1.204
1.345
1.365
1.224
1.089
0.941
1.535

<.0001
<.0001
<.0001
<.0001
0.7236
<.0001
<.0001

REF
1.096
1.302
1.387
1.154
1.14
0.912
1.408

REF
2.526
1.343
0.685
1.25
1.257

2.434
1.249
0.618
1.058
1.209

2.62
1.444
0.759
1.478
1.307

<.0001
<.0001
<.0001
0.0088
<.0001

REF
2.618
1.142
0.932
1.697
1.419

2.482
0.993
0.769
1.393
1.329

2.762
1.313
1.13
2.067
1.515

<.0001
0.062
0.4741
<.0001
<.0001

<.0001

REF
1.013

0.974

1.055

0.5097

REF
1.187

1.163

1.212

Yes
No
Don't Know

REF
0.844
0.696

Yes
No

REF
0.961

Less than $25,000
$25,000-$50,000
$50,000-$75,000
$75,000+

0.817
0.56

0.872
0.864

<.0001
0.001

REF
0.737
0.628

0.699
0.366

0.777
1.076

<.0001
0.0905

REF
0.956

0.914

1.001

0.0539

Binge Drinker
0.936

0.987

0.0038

1.068
0.995
0.979
REF

1.028
0.962
0.945

1.109
1.029
1.013

0.0007
0.7494
0.2161

1.164
1.166
1.089
REF

1.083
1.092
1.015

1.25
1.245
1.168

<.0001
<.0001
0.0174

18-24
25-34
35-44
45-54
55-64
65+

3.687
6.704
6.655
3.99
2.174
REF

3.469
6.402
6.371
3.832
2.098

3.919
7.02
6.951
4.154
2.252

<.0001
<.0001
<.0001
<.0001
<.0001

8.827
8.114
5.352
3.316
2.068
REF

7.77
7.229
4.772
2.962
1.863

10.027
9.108
6.002
3.713
2.295

<.0001
<.0001
<.0001
<.0001
<.0001

Everyday
Some days
Not at all

1.151
1.014
REF

1.123
0.981

1.18
1.048

<.0001
0.4057

1.14
1.114
REF

1.09
1.053

1.193
1.178

<.0001
0.0001

Married
Divorced
Widowed
Separated
Never Married

REF
1.629
0.91
1.647
1.368

1.582
0.873
1.56
1.324

1.677
0.948
1.74
1.414

<.0001
<.0001
<.0001
<.0001

1.737
1.073
1.854
1.699

1.953
1.32
2.2
1.907

<.0001
0.001
<.0001
<.0001

Income Category

Age Category
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Current Smoking Status

Marital Status
REF
1.842
1.19
2.02
1.8

*High Risk Behaviors and Sexual Orientation were excluded from the model due to data only
available for certain years

(OR=0.77; 95%CI= 0.72,0.83; p<0.0001), controlling for the other variables in the
multivariate regression model.
Non-Hispanic blacks were 2.6 times (95%CI= 2.48, 2.76; p<0.0001) as likely to
self-report having been tested for HIV within the past 12 months compared to NH whites.
Those without health insurance had 0.74 times the odds of having been tested for HIV
within the past 12 months compared to those with health insurance, controlling for the
other variables in the model. The younger the participant the more likely they were to
report being tested for HIV within the past year (OR=8.83 95%CI= 7.77, 10.03;
p<0.0001 for the 18-24 age group) compared to those 65+. Smoking status was also
positively associated with HIV testing within the past year as current smokers and those
who report smoking some days were 1.1 times as likely to have reported having had an
HIV test within the past 12 months compared to those who do not smoke at all,
controlling for the other variables.
The results from the multivariate logistic regression analysis for years the BRFSS
collected data on HIV high risk behavior exposures are displayed in table 6.4, which
assessed associations between the pooled data on the demographic variables from the
years with collected data (2011–2012 and 2016-2017) and having ever been tested for
HIV, after model adjustment.
The odds of having ever been tested for HIV are 1.91 times (95%CI= 1.81, 2.02;
p<0.0001) as likely for those who have reported HIV high risk behavior involvement
compared to those who have not been involved in any of those activities, controlling for
the other variables in the model. No other factor significantly changed in its relationship
to HIV testing, after adjusting for high risk behaviors.
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Table 6.4. Multivariate Logistic Regression Sub-Analysis of Ever and within Past-Year Testing of HIV for Years
with Data on HIV High Risk Behavior Involvement, BRFSS 2011–2012, 2016-2017
Variable
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Educational Attainment
Less than H.S.
HS Graduate
Some College
College Graduate
Current Employment Status
Employed
Self-Employed
Out of Work <1 year
Out of Work>1 year
Homemaker
Student
Retired
Unable to Work
Race/Ethnicity
NH White
NH Black
NH American Indian/Alaskan
NH Asian
NH Native Hawaiian/Pacific
Islander
Hispanic
Gender
Male
Female
Have Health Insurance
Yes
No

Odds Ratio
0.609
0.636
0.862
REF

Ever
95% Confidence
Limits

P-Value

0.582
0.615
0.835

0.637
0.657
0.889

<.0001
<.0001
<.0001

REF
1.212
1.346
1.255
1.244
1.014
0.965
1.581

1.159
1.269
1.178
1.179
0.933
0.925
1.514

1.267
1.427
1.337
1.312
1.103
1.006
1.65

<.0001
<.0001
<.0001
<.0001
0.7405
0.096
<.0001

REF
2.992
0.951
0.745

2.866
0.859
0.639

3.123
1.052
0.868

1.329

1.187

1.343

Odds
Ratio
0.736
0.768
0.944
REF

Past-Year
95% Confidence
Limits

P-Value

0.667
0.713
0.88

0.812
0.827
1.013

<.0001
<.0001
0.1107

REF
1.005
1.374
1.352
1.14
1.215
0.96
1.402

0.908
1.23
1.208
0.995
1.065
0.843
1.288

1.112
1.536
1.512
1.305
1.387
1.092
1.525

0.9284
<.0001
<.0001
0.0592
0.0038
0.5331
<.0001

<.0001
0.3274
0.0002

REF
2.635
1.085
1.14

2.453
0.883
0.865

2.83
1.335
1.503

<.0001
0.3274
0.0002

1.488

<.0001

1.833

1.482

2.268

<.0001

1.283

1.406

<.0001

1.517

1.391

1.654

<.0001

REF
1.195

1.167

1.224

<.0001

REF
1.031

0.978

1.088

<.0001

REF
0.797

0.769

0.826

<.0001

REF
0.742

0.69

0.797

<.0001

Don't Know

0.694

0.519

0.929

0.0141

0.759

0.347

1.663

0.0141

Yes
No

REF
0.964

0.935

0.994

0.0196

REF
0.952

0.895

1.012

0.0196

1.083
1.009
0.932
REF

1.036
0.971
0.896

1.132
1.049
0.969

0.0005
0.6355
0.0005

1.126
1.178
1.034
REF

1.023
1.079
0.94

1.24
1.287
1.136

0.0005
0.6355
0.0005

4.257
7.946
7.734
4.298
2.258
REF

3.963
7.532
7.356
4.105
2.168

4.573
8.383
8.132
4.501
2.353

<.0001
<.0001
<.0001
<.0001
<.0001

8.376
7.755
5.381
3.344
2.104
REF

7.062
6.655
4.622
2.882
1.834

9.934
9.036
6.263
3.879
2.415

<.0001
<.0001
<.0001
<.0001
<.0001

1.141
1.006
REF

1.11
0.968

1.174
1.046

<.0001
0.7586

1.089
1.069
REF

1.025
0.993

1.156
1.152

<.0001
0.7586

1.679
0.878
1.561
1.327

1.793
0.963
1.776
1.433

<.0001
0.0004
<.0001
<.0001

1.704
1.061
1.786
1.572

1.994
1.386
2.247
1.836

<.0001
0.0004
<.0001
<.0001

1.805

2.02

<.0001

1.59

1.855

<.0001

0.944

1.894

0.102

0.578

3.357

0.4606

Binge Drinker
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Income Category
Less than $25,000
$25,000-$50,000
$50,000-$75,000
$75,000+
Age Category
18-24
25-34
35-44
45-54
55-64
65+
Current Smoking Status
Everyday
Some days
Not at all
Marital Status
Married
Divorced
Widowed
Separated
Never Married
HIV High Risk Behavior
Yes
No
Don't Know

REF
1.735
0.919
1.665
1.379
1.909
REF
1.337

REF
1.843
1.213
2.003
1.699
1.717
REF
1.393

Furthermore, the results from the logistic regression analysis for years where the
BRFSS collected data on HIV high risk behavior exposures displayed in table IV, which
assessed associations between the pooled data on the demographic variables from the
years with collected data (2011–2012 and 2016-2017) and reporting their last HIV test as
being within 12 months prior to their interview date, after model adjustment. The odds of
having been tested for HIV within 12 months among those who had been involved in
HIV high risk behaviors is 1.7 times (95%CI=1.59,1.86; p<0.0001) as likely as those who
reported not having been involved in any HIV high risk behaviors, controlling for the
other variables in the model. Several employment statuses (self-employed and
homemaker) significantly changed in its relationship to HIV testing, after adjusting for
HIV high risk behaviors.
The results from the multivariate logistic regression analysis for years where the
BRFSS collected data on sexual orientation are displayed in table 6.5, which assessed
associations between the pooled data on the demographic variables from the years the
BRFSS collected data on sexual orientation (2014-2017) and having ever been tested for
HIV, after model adjustment. The odds of having ever been tested for HIV are 3.3 times
as likely among those who reported as lesbian/gay compared to those who reported as
straight. Inversely, those who were unsure of their sexual orientation were 0.78 times as
likely to have reported as ever having been tested for HIV compared to those who
reported as straight, controlling for the other variables in the model.
The odds of having been tested for HIV within 12 months among those who
identify as lesbian/gay are 2.0 times (95%CI= 1.66, 2.43, p<0.0001) as likely as those
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Table 6.5 Multivariate Logistic Regression Sub-Analysis Results of Ever and within Past-Year Testing of HIV for
Years with Data on Sexual Orientation, BRFSS 2014-2017
Variable

Odds Ratio

95% Confidence
Limits

P-Value

Odds
Ratio

95% Confidence
Limits

P-Value

Educational Attainment
Less than H.S.

0.609

0.582

0.637

<.0001

0.609

0.582

0.637

<.0001

HS Graduate

0.636

0.615

0.657

<.0001

0.636

0.615

0.657

<.0001

Some College

0.862

0.835

0.889

<.0001

0.862

0.835

0.889

<.0001

College Graduate

REF

REF

Employed

REF

REF

Self-Employed

1.212

1.159

1.267

<.0001

1.212

1.159

1.267

<.0001

Out of Work <1 year

1.346

1.269

1.427

<.0001

1.346

1.269

1.427

<.0001

Out of Work>1 year

1.255

1.178

1.337

<.0001

1.255

1.178

1.337

<.0001

Homemaker

1.244

1.179

1.312

<.0001

1.244

1.179

1.312

<.0001

Student

1.014

0.933

1.103

0.7405

1.014

0.933

1.103

0.7405

Retired

0.965

0.925

1.006

0.096

0.965

0.925

1.006

0.096

Unable to Work

1.581

1.514

1.65

<.0001

1.581

1.514

1.65

<.0001

NH White

REF

NH Black

2.992

2.866

3.123

<.0001

2.992

2.866

3.123

<.0001

NH American Indian/Alaskan

0.951

0.859

1.052

0.3274

0.951

0.859

1.052

0.3274

Current Employment Status
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Race/Ethnicity

REF

NH Asian

0.745

0.639

0.868

0.0002

0.745

0.639

0.868

0.0002

NH Native Hawaiian/Pacific Islander

1.329

1.187

1.488

<.0001

1.329

1.187

1.488

<.0001

Hispanic

1.343

1.283

1.406

<.0001

1.343

1.283

1.406

<.0001

Male

REF

Female

1.195

1.167

1.224

<.0001

Yes

REF

No

0.797

0.769

0.826

<.0001

0.797

0.769

0.826

<.0001

Don't Know

0.694

0.519

0.929

0.0141

0.694

0.519

0.929

0.0141

Yes

REF

No

0.964

0.935

0.994

0.0196

0.964

0.935

0.994

0.0196

Less than $25,000

1.083

1.036

1.132

0.0005

1.083

1.036

1.132

0.0005

$25,000-$50,000

1.009

0.971

1.049

0.6355

1.009

0.971

1.049

0.6355

$50,000-$75,000

0.932

0.896

0.969

0.0005

0.932

0.896

0.969

0.0005

$75,000+

REF

18-24

4.257

3.963

4.573

<.0001

4.257

3.963

4.573

<.0001

25-34

7.946

7.532

8.383

<.0001

7.946

7.532

8.383

<.0001

35-44

7.734

7.356

8.132

<.0001

7.734

7.356

8.132

<.0001

45-54

4.298

4.105

4.501

<.0001

4.298

4.105

4.501

<.0001

Gender
REF
1.167

1.224

<.0001

1.195

Have Health Insurance
REF

Binge Drinker
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REF

Income Category

REF

Age Category

55-64

2.258

2.168

2.353

<.0001

2.258

2.168

2.353

<.0001

65+

REF

Everyday

1.141

1.11

1.174

<.0001

1.141

1.11

1.174

<.0001

Some days

1.006

0.968

1.046

0.7586

1.006

0.968

1.046

0.7586

Not at all

REF

REF

Married

REF

REF

Divorced

1.735

1.679

1.793

<.0001

1.735

1.679

1.793

<.0001

Widowed

0.919

0.878

0.963

0.0004

0.919

0.878

0.963

0.0004

Separated

1.665

1.561

1.776

<.0001

1.665

1.561

1.776

<.0001

Never Married

1.379

1.327

1.433

<.0001

1.379

1.327

1.433

<.0001

Straight

REF

Lesbian/Gay

3.267

2.817

3.789

<.0001

2.007

1.659

2.427

<.0001

Bi-sexual

2.112

1.86

2.399

<.0001

1.651

1.395

1.954

<.0001

Other

0.865

0.642

1.166

0.3401

1.252

0.636

2.465

0.5153

Not Sure

0.773

0.583

1.025

0.0736

0.942

0.55

1.614

0.8278

REF

Current Smoking Status

Marital Status
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Sexual Orientation

REF

who identify as straight and those who identified as Bi-sexual were 1.66 times (95%CI=
1.40, 1.95; p<0.0001) as likely. Those who are reported as unsure of their sexual
orientation were less likely (OR=0.94) to have been tested within 12 months of their
interview date than those who reported a straight, and those the value is not considered
statistically significant (95%CI=0.55, 1.62; p=0.83).
6.5 Discussion
Our study utilized BRFSS data from 2011-2017 to assess temporal trends as well
as demographic and socioeconomic factors associated with HIV testing among adults
across the U.S. Overall, an average of 36.07% of adults who were surveyed during those
years, reported as having ever been tested for HIV (APC of 1.2%) and 4.78% (APC of 0.29%) reported as having been tested for HIV within the past 12 months prior to their
interview date. After adjustment for the covariates used in the multivariate logistic
regression, our findings aligned with results from previous literature (Ford; Ansa; Gaines;
Henderson; Ohl) done on different parts of the county, that gender (female), race (NHBlack), age (25-34 age group), and income level (<$25,000), and being single are all
positively associated with higher odds for both being tested for HIV ever and tested for
HIV within the past year.
We conducted a sub-analysis for years that collected data on HIV high risk
behaviors (2011-2012, 2016-2017) and our findings also aligned with previous results
(Gaines; Henderson) that reported high risk behaviors were positively associated with
higher odds of both reporting being tested for HIV ever and within the past year.
Additionally, we conducted a sub-analysis for years that collected data on sexual
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orientation (2014-2017) and our findings indicated that sexual orientation (lesbian/gay
and bi-sexual) was positively associated with both reporting as having ever been tested
for HIV and reporting their last HIV test as within the past year.
Our study had a few strengths and limitations. A major strength of the study is the
use of large nationally represented sample of BRFSS survey data, including the most
recently released year (2017). Unlike other studies done targeting specific urban settings
or specific age groups, our study provides an up to date comprehensive review of BRFSS
data across the entire country for all adult age categories and includes updated data on
major HIV risk predictors: HIV high risk behaviors and sexual orientation.
Inversely, a major limitation is the fact that the BRFSS relies on self-reported data
which opens the data up to bias (recall and non-response bias based on refusal to answer)
though we used survey weights to limit the potential bias. That being said, there have a
been a few studies that specifically discussed the validity of self-reported HIV testing
data under certain circumstances (Henderson; An) and indicated a favorable evaluation
when compared to medically reported HIV tests. Due to the nature of the survey data
collection methodology, there may be pockets of the population left out of the survey due
to lack of access to land and cell service, particularly in rural areas.
6.6 Conclusion
The findings of our study showed that an average of slightly more than 1/3rd of
those surveyed during the 2011-2017 BRFSS reported as ever having been tested for HIV
(36.07%) and approximately only 1 out of every 20 surveyed, reported their last HIV test
being within the past year. These results indicate the continued need for emphasis on
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nation-wide targeted interventions and policies to address disparities regarding the
utilization of HIV testing across the country.
The impact of the CDC’s HIV testing “opt-out” recommendations (Galletly)
established in 2006 have seemingly plateaued as there is a slight APC in reported HIV
testing percentages and hence the need for further evaluation and assessment of policies
moving forward. An increase in the utilization of HIV testing has always been a key
component in combating and ultimately stemming the HIV epidemic, particularly among
high risk groups (minorities, high risk behavior involvement, sexual orientation and those
with lower incomes). While these target groups are reporting at higher rates and hence
having higher likelihoods of reporting as having been tested for HIV, there is still much
work to be done to increase those percentages further, particularly regarding recent HIV
testing where the percentages are quite poor across the spectrum.
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CHAPTER 7

CONCLUSIONS AND RECOMMENDATIONS
7.1 Conclusions
The findings from this dissertation have provided further insight into HIV testing
utilization trends and access to HIV testing across the U.S. south. Furthermore, we
produced and validated estimated HIV prevalent case counts for all counties across the
continental U.S., including counties with previously unreported counts. We did so using
innovative small area estimation techniques which along with providing HIV estimates,
provides a basis for future researchers to estimate area-level health outcomes using solely
area-level data in the model.
Chapter 4 dealt with assessing spatial access to HIV testing facilities across the
U.S. south to identify how access differs by levels of rurality and key demographic and
socioeconomic factors. The results of our study confirmed that as rurality increased, so
too did the percentage of CTs that were located farther than 30 minutes from a testing
facility. It showed that when controlling for other covariates, the higher the rate of
uninsured 18-64-year olds, the less likely that the CT is located within 30 minutes of any
HIV testing facility. We also identified consistently high levels of economic deprivation
in rural parts of most states particularly in the deep south states. Texas in particular, had
the most visable intersection of rurality, area deprivation and poor supply of HIV testing.
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In chapter 5, we provided a more complete picture of the HIV burden across the
U.S. using small area estimation techniques to produce county-level HIV case counts for
areas with missing or suppressed data. These estimated case counts can be useful to
policymakers, public health practitioners, healthcare providers and others for identifying
the best locations for outreach efforts and targeted interventions, as well as provide
evidence for resource allocation/funding decisions. The use of publicly available arealevel secondary data in the model is a unique feature that can be used to estimate other
area-level health outcomes in a cost-effective and timely manner.
Finally, we explored temporal trends and related predictors of utilization of HIV
testing across the U.S. using the BRFSS survey in chapter 6. Our findings showed slight
improvement in testing percentages among those who reported having ever been tested
for HIV from 2011 to 2017. There was a slight decrease among those who reported
having been tested for HIV within the past year of their interview date. Our results were
consistent with results reported by previous studies, though those studies focused on
specific urban geographic regions or age groups while our study scale was nationwide.
Females, those who identify as lesbian/gay and NH blacks were all significantly more
likely to report having been tested for HIV ever and within the past year as their
counterparts in each subcategory.
7.2 Recommendations
Recommendations for the use of the findings from this dissertation include using
the data to support more interventions targeting HIV testing, particularly regularly HIV
testing (vs. one-time/ “ever tested”). Such interventions should be targeted at areas with
disproportionate barriers regarding access to HIV testing (e.g., poor transportation,
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farther distance to facilities, lack of health insurance, etc.). Our findings showed that only
approximately 1/3rd of all respondents to the HIV section of the BRFSS had ever been
tested for HIV, which sorely hampers the goal of stemming HIV transmission. HIV
continues to be a major issue particularly in the rural south where the combination of
high socioeconomic deprivation (such as lower rates of insurance, lower educational
attainment, higher poverty rates, higher levels of social stigma among other factors), lack
of supply of HIV testing and treatment facilities, and high HIV burden will continue to
drive the epidemic until major action is taken to stem the transmission of HIV and
address its related risk indicators (i.e., poor SES, high HIV risk behaviors) that lead to
higher risk of contracting and transmitting HIV.
Recommendations for future research based off the work done in this dissertation
would be 1) obtain geocoded addresses for all HIV treatment facilities in the south to
spatially examine access to the full continuum of HIV care at the local level 2) use SAE
or similar statistical methodology to predict future HIV estimates to identify areas that
may be susceptible to HIV outbreaks based on current HIV-risk indicators and 3) case
studies on successful implementation of outreach efforts to increase HIV testing
utilization at the local/state level or among specific subpopulations, to identify successful
strategies to bring to disseminate more broadly.
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APPENDIX A:
LIST OF VARIABLES IN THE AREA DEPRIVATION INDEX (ADI)

•

Percent of the population aged 25 and older with less than 9 years of education

•

Percent of the population aged 25 and older with at least a high school diploma

•

Percent employed persons aged 16 and older in white-collar occupations

•

Median family income in US dollars

•

Income disparity

•

Median home value in US dollars

•

Median gross rent in US dollars

•

Median monthly mortgage in US dollars

•

Percent of owner-occupied housing units

•

Percent of civilian labor force population aged 16 years and older who are
unemployed

•

Percent of families below federal poverty level

•

Percent of the population below 150% of the federal poverty threshold

•

Percent of single-parent households with children less than 18 years of age

•

Percent of households without a motor vehicle

•

Percent of households without a telephone

•

Percent of occupied housing units without complete plumbing

•

Percent of households with more than 1 person per room
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APPENDIX B:
STANDARD ERRORS OF AVERAGE CENSUS TRACT
DEMOGRAPHICS STRATIFIED BY ACCESS
Table B.1 Standard Errors of Average Demographics of Census Tracts within and
Outside of 30-minutes of a Testing Facility

Variable

No Access SE

Access SE

American Indian
Asian
Black
Hawaiian/Pacific Islander
Non-Hispanic White

0.134
0.121
0.682
0.020
0.801

0.018
0.033
0.157
0.002
0.161

Hispanic
Not Hispanic

1.180
1.180

0.141
0.141

0.778
2.858
3.516
1.295
1.212
10.078
0.787
1378.27
0.266

0.122
0.343
0.269
0.150
0.162
0.900
0.135
243.31
0.033

Overall
Under 18
18-64
65+
Female
Male

0.592
0.718
0.683
0.095
0.537
0.625

0.056
0.048
0.078
0.025
0.055
0.062

Overall
Under 18
18-64
65+
Female
Male

0.695
1.056
0.690
0.597
0.668
0.705

0.080
0.122
0.075
0.065
0.086
0.078

Race (%)

Ethnicity (%)

Education (% with bachelor’s degree)
Overall
American Indian
Asian
Black
Hispanic/Latino
Hawaiian/Pacific Islander
Non-Hispanic White
Income (average $)
Unemployment Rate (%, ages 16+)
Uninsured (%)

Poverty Rate (%)
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APPENDIX C:
FULL LIST OF BRFSS QUESTIONS AND ANSWER CHOICES

Table C.1 Full List of BRFSS Questions and Answer Choices

Questions
Have you ever been tested
for HIV? Do not count tests
you may have had as part of
a blood donation. Include
testing fluid from your
mouth

Variables

Answers

HIVTST6

1=yes
0=no
7=don't know
9=refused

Ever been Tested for HIV

HIVTST6
changed to
HIVEVER

Not including blood
donations, in what month
and year was your last HIV
test? (If response is before
January 1985, code
"777777".)

1=yes
0=no, missing, refused

HIVTSTD3
_____

Tested within Past-Year

HIVTSTD3
changed to
WITHIN12

Level of Education
Completed

_EDUCAG

Are you currently…?

Reference Group

1=yes
0=no
1= none
2=HS Graduate
3=Some College
4=College Graduate
9=Don’t know, missing

(2011-2012)
EMPLOY

1=employed
2=self employed
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REF
REF

3=out of work>1 yr
4=out of work <1 yr
5=homemaker
6=student
7=retired
8=unable to work
9=retired
(2013-2017)
EMPLOY1
New Variable
EMPLOY2
Race/ethnicity categories
(2011-2012)
ORACE2
(2013-2017)
_RACE
New Variable
RACE2

Indicate Sex of Respondent

SEX

Is your annual household
income from all sources:

INCOME2

Annual Household Income
(condensed)

Do you have any kind of
health care coverage,
including health care
insurance, pre-paid plans
such as HMOs, or

1=white only, non hispanic
2=black only, non hispanic
3=american indian/alaskan
only, non hispanic
4=asian only, non hispanic
5=native hawaiian/P.I. only,
non hispanic
6=other race only, non hispanic
7=multi-racial, non hispanic
8=hispanic
9=don't know, refused
1=male
2=female
9=refused
1=<10,000
2=<15,000
3=<20,000
4=<25,000
5=<35,000
6=<50,000
7=<75,000
8=>75,000
77=don't know
99=refused

New Variable
INCOME3

1= <25,000
2= 25,000-50,000
3= 50,000-75,000
4= >75,000
77=don't know
99= refused

HLTHPLN1

1=Yes
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REF

REF

REF

REF

REF

government plans such as
medicare, or indian health
services?

6 level age imputed category

I am going to read you a list.
When I am done, please tell
me if any of the situations
apply to you. You do not
need to tell me which one.
You have injected any drug
other than those prescribed
for you in the past year. You
have been
treated for a sexually
transmitted disease or STD
in the past year. You have
given or received money or
drugs in exchange for sex in
the past year.

Binge drinkers (males
having five or more drinks
on one occasion, females
having four or more drinks
on one occasion)

Do you now smoke
cigarettes every day, some
days, or not at all?

Are you: (marital status)

2=No
7=Don't Know
9=Refused
1=18-24
2=25-34
3=35-44
4=45-54
5=55-64
6=65+

_AGE_G

REF

(2011-2012)
HIVRISK3

(2016)
HIVRISK4
(2017)
HIVRISK5
New variable
HIVRISK

1=yes
2=no
7=don't know
9=refused

REF

1=no
2=yes
9=don't know or refused

REF

_RFBING5

SMOKDAY2

MARITAL

1=every day
2=some day
3=not at all
7= don't know
9= refused
1=married
2=divorced
3=widowed
4=separated
5=never married
6=member of unmarried couple
9=refused
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REF

REF

Do you consider yourself to
be: (We ask this question in
order to better understand
the health and health care
needs of people with
different sexual
orientations.)

1=straight
2=lesbian/gay
3=bi-sexual
4=other
7=not sure
SXORIENT
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